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Glossary of terms 
 
ADC apparent diffusion coefficient 
ADP Adenosine diphosphate 
AFP alpha fetoprotein 
ALT alanine transaminase 
ATP Adenosine triphosphate 
AUC area under the curve 
beta-hCG beta human chorionic gonadotrophin 
BM Basement membrane 
CA Carbonic anhydrase 
CA 125 cancer antigen 125 
CBAL Core Biochemical Assay Laboratory) 
CMO Chief Medical Officer 
COV coefficient of variation 
CR Complete Response 
CRUK Cancer Research UK 
CT Computed tomography 
Dapp apparent diffusion 
DKI Diffusion kurtosis imaging 
DNA Deoxyribonucleic acid 
DNP dynamic nuclear polarization 
DWI Diffusion weighted imaging 
ECM Extracellular matrix 
ECOG Eastern Cooperative Oncology Group 
EPA electron paramagnetic agent 
ETC electron transport chain 
EVf extracellular volume fraction 
FA Flip angle 
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FDG-PET fluorodeoxyglucose positron emission tomography 
18F-FDG 18F-fluorodeoxyglucose 
18F-FDG-PET 
18F-fluorodeoxyglucose positron emission 
tomography 
FIGO Fédération Internationale de Gynécologie et d'Obstétrique 
FoV field of view 
FSPGE fast spoiled gradient echo 
FWHM Full width at half maximun 
GCP Good clinical practice 
GE gradient echo 
GE General electric 
GLUT Glucose transporter 
GTP Guanosine triphosphate 
H&E haematoxylin and eosin 
HGSOC high grade serous ovarian cancer 
HP 13C-MRI Hyperpolarized carbon-13 magnetic resonance imaging 
HP 13C-MRI Hyperpolarized carbon-13 MRI 
ICC Intraclass correlation coefficient 
ICH International conference on harmonisation 
IHC immunohistochemistry 
IR Inversion recovery 
IT inversion time 
IV intravenous 
IVf intracellular volume fraction 
IWS intracellular weighted sodium 
Kapp apparent kurtosis 
kPL Rate constant for pyruvate to lactate exchange 
LDH Lactate dehydrogenase 
MCT monocarboxylate transporter 
MISSION-Ovary (Molecular Imaging and Spectroscopy with Stable Isotopes in Oncology and Neurology - Ovary 
13 
 
MR  Magnetic resonance 
MRC Medical Research Council 
MRF magnetic resonance fingerprinting 
MRI Magnetic resonance imaging 
MT Magnetization transfer 
MTR magnetization transfer ratio 
NACT neoadjuvant chemotherapy 
NAD+ Nicotinamide adenine dinucleotide (oxidized form) 
NADH Nicotinamide adenine dinucleotide (reduced form) 
[Na+EC] Extracellular sodium concentration 
[Na+IC] Intracellular sodium concentration 
23Na-MRI Sodium magnetic resonance imaging 
NAWM normal appearing white matter 
NEX number of excitations 
NHS National Health Service 
OECD Organisation for Economic Co-operation and Development 
PARP poly ADP-ribose polymerase 
PARPi PARP inhibitor 
PCOD Polycystic ovarian disease 
PD Progressive Disease 
PD Proton density 
PDC Pyruvate dehydrogenase complex 
PDH dehydrogenase enzyme complex 
PET Positron emission tomography 
PID pelvic inflammatory disease 
PIS Patient information sheet 
PR Partial Response 
rB1 Relative B1 
REC Research Ethics Committee 
RECIST Response Evaluation Criteria In Solid Tumours 
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RF radiofrequency 
RMI risk of malignancy index 
RMS COV root mean square coefficient of variation 
ROCA risk of ovarian cancer algorithm 
ROI Region of interest 
RRID Research Resource Identifier 
S signal 
S.D. standard deviation 
SD Stable Disease 
SNR Signal to noise 
SoS stack-of-stars 
SSFP Steady-state free precession 
SUV standardized uptake value 
SUVmax Maximum standardized uptake value 
T1W T1-weighted 
T2W T2-weighted 
TCA Tricarboxylic acid 
TE Echo time 
TR Repetition time 
TSC Tissue sodium concentration 
TSC tissue sodium concentration 
US ultrasound 
UTE ultra-short echo time 
VEGF Vascular endothelial growth factor 
VOI volume of interest 
α Flip angle 
αtrue True flip angle 
ρc cellular density 
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Chapter 1 
 
Research aims and study design 
________________________________ 
 
1.1 Background   
 
Ovarian cancer has the highest mortality of any gynaecologic cancer in the developed world. 
In the UK, the Chief Medical Officer (CMO) reported 4,227 deaths from the condition in 
2016. Mortality from ovarian cancer in the UK is among the highest for OECD (Organisation 
for Economic Co-operation and Development) nations, with a 5-year survival rate of only 
36% (1). In the UK, ovarian cancer currently accounts for 5% of all female cancer deaths, 
making it the fifth-most lethal cancer in women (2). Over 7,000 new cases of ovarian cancer 
are currently diagnosed each year and 90% of these new cases are of the epithelial subtype, 
the deadliest form of ovarian cancer. 
Several new magnetic resonance imaging techniques in cancer have recently been shown to 
have clinical relevance for the detection, management and monitoring of malignancies. For 
example, diffusion kurtosis imaging (DKI) in glioma has been shown to differentiate high 
grade from low grade disease (3, 4), sodium imaging in the brain and breast is able to 
differentiate cancerous from normal tissue (5, 6) and one study showed that hyperpolarized 
carbon-13 MRI in the prostate may be more sensitive than proton MRI at detecting 
malignancies (7). Evidence is also emerging that some older magnetic resonance imaging 
techniques like magnetization transfer (MT) imaging may have a role in clinical medicine for 
imaging microstructural cancer properties like fibrosis (8). One of the newest forms of MRI, 
magnetic resonance fingerprinting (MRF) has also demonstrated the ability to accelerate 
image acquisition which could aid clinical translation for a range of different proton MRI 
techniques (9). 
Despite the promise of these magnetic resonance imaging methods, there has been a lack of 
application of these techniques to ovarian cancer. This is despite ovarian cancer being 
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acknowledged as a cancer where improvements in care are desperately required (10). The 
reasons behind the lack of usage of new imaging in ovarian cancer are not clear but may 
relate to the difficulty of imaging a large, complex anatomical area such as the abdomen and 
pelvis and to the lack of definitive evidence of clinically relevant information that may be 
gained from novel imaging techniques that can influence the limited management options 
currently available for ovarian cancer patients. 
 
1.2 Aims of this research 
The overarching aim of this PhD was to recruit a cohort of patients with ovarian cancer and 
to evaluate on the ovarian cancer lesions of these patients the use of metabolic and 
microstructural imaging techniques that have previously shown promise for clinical 
applications in oncology.  
Secondary aims of this PhD were: to demonstrate the feasibility of imaging in a clinical 
setting for those techniques that had never previously been applied to ovarian cancer, and 
for all the techniques evaluated apart from MRF: to find correlations of the ovarian cancer 
tissue properties and patient demographics with the imaging results. 
The reason these aims were chosen was because of the perceived need by the research 
team for an improvement in the treatment of ovarian cancer that could potentially come 
from a better understand of in vivo ovarian cancer biology provided by imaging. It was also 
felt that a furthering of knowledge about the biological origin of the imaging signal for the 
various techniques from a comparison with ovarian cancer tissue could help to identify 
future clinical applications for the imaging.  
The imaging techniques selected for this study were DKI, sodium MRI, MT imaging, 
hyperpolarized carbon-13 MRI and MRF. These were selected as they have all shown 
potential for clinical applications in cancer imaging but have not yet been fully explored for 
their utility in the assessment of ovarian cancer or any sub-population of ovarian cancer 
patients. The use of these techniques in ovarian cancer therefore represent a gap in 
scientific knowledge which this PhD seeks to help address. 
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1.3 Study design and protocol 
The patient imaging in this study was performed as part of the MISSION-Ovary (Molecular 
Imaging and Spectroscopy with Stable Isotopes in Oncology and Neurology - Ovary) clinical 
study. Much of the first year of this PhD was spent designing the protocol for MISSION-ovary 
and gaining ethical approval for the study, in addition to performing some related in vitro 
cell experiments that are presented in Chapter 8.  
MISSION-ovary was primarily funded by a grant from Cancer Research UK but also 
benefitted from the use of equipment and the assistant of staff funded by the Wellcome 
Trust. MISSION-ovary was designed around hyperpolarized carbon-13 imaging in high grade 
serous ovarian cancer (HGSOC) patients, with permission also obtained from the ethics 
committee and sponsors for non-invasive proton imaging, sodium imaging and FDG-PET 
(fluorodeoxyglucose positron emission tomography) imaging.  
Hyperpolarized carbon-13 MRI was initially intended as the primary research focus of this 
PhD as based on pre-clinical trials this imaging technique had the potential for the most 
clinically impactful results, including the non-invasive mapping of in vivo enzyme activity 
(11) and the early detection of response to cancer treatment (12). Unfortunately, due to 
global shortages in the specialist materials like the clinical grade carbon-13 labelled 
molecules required for hyperpolarized carbon-13 imaging and because of the time 
constraints for completing this PhD, the focus of this research project shifted more towards 
proton and sodium imaging than carbon-13 imaging as time progressed.  
The MISSION-ovary study protocol nevertheless was still used to outline the eligibility 
criteria for participants, patient recruitment methods, the time points of imaging and tissue 
collection during the treatment course and the general tissue analysis methods that would 
be used for the alternative imaging techniques evaluated in this PhD in place of 
hyperpolarized carbon-13 MRI. 
The protocol for MISSION-ovary was reviewed and approved by the South Cambridge 
Research Ethics Committee (REC). Patients with ovarian masses were identified through the 
gynaecological oncology multidisciplinary team meetings and clinics at Cambridge University 
Hospitals NHS Foundation Trust, Addenbrooke’s hospital. The clinical team was responsible 
for the initial approach to patients and for determining whether patients might be suitable 
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for participation. If deemed suitable be the clinical team, potential participants were then 
offered a meeting with researchers to discuss the details of the research study further. 
 
To be included in the study the patients needed to meet the following inclusion criteria: 
1. Be 18 years or older. 
2. Have a confirmed or likely diagnosis of HGSOC. 
3. Be aware of their diagnosis. 
4. Be a likely surgical candidate who is fit for possible surgery. 
5. Have no contraindications to the use of the intravenous contrast agents involved in 
the study. 
6. Be able to provide written informed consent according to ICH (International 
conference on harmonisation), GCP (good clinical practice), national and local 
regulations. 
 
7. Have a negative pregnancy test, either urinary or blood prior to enrolment if of 
childbearing potential. 
8. Have ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1. 
9. Express willingness and ability to comply with scheduled visits, laboratory tests, 
imaging and other study procedures. 
 
The following criteria excluded patients from the study: 
1. Any disorder that could adversely affect levels of pyruvate or lactate such as diabetes 
mellitus. 
2. The use of medications that may affect levels of pyruvate or lactate such as 
metformin or insulin.  
3. Known allergy or adverse reaction to any of the injected contrast agents proposed for 
use in the study. 
4. Pregnancy or breastfeeding. 
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5. Other severe acute or chronic medical or psychiatric conditions that may increase the 
risk associated with study participation or in the judgement of the investigators make 
it undesirable for the patient to enter the study. 
6. Laboratory abnormalities that may have an unknown or unpredictable impact on 
study results. 
7. Unsuitability for magnetic resonance imaging e.g. severe obesity, inability to lie still or 
contraindicated metal implants such as the intrauterine contraceptive device.  
 
Permission was also obtained from the REC to collect tissue before and after imaging via 
percutaneous biopsy or a surgical procedure. The approved study protocol detailed the main 
analytic methods to be applied to tissue including genetic profiling, histology and 
immunohistochemistry. 
 
1.4 Research team members and roles 
Due to the multidisciplinary nature of imaging in oncology and the specialist types of 
imaging evaluated here, a large and diverse team was involved in the MISSION-ovary 
research project and this PhD. The contributing research team included physicists, 
oncologists, surgeons, radiologists, pathologists, nurses, radiographers and laboratory 
technicians. 
After study approval by the REC, my role as a PhD student included the overall co-ordination 
of study activities. I was the primary person responsible for identifying participants, 
explaining the study and providing the patient information sheet (PIS) to potential 
participants. I also contacted the patients to elicit their final decision on participation, liaised 
with the radiology department to book scans, arranged supporting staff such as 
radiographers and physicists to be present to assist with imaging at the scheduled scan 
dates, assisted with the collection of tissue at surgery, transferred tissue that was collected 
for further laboratory analysis, analysed the imaging and tissue measurement results, 
performed the statistical analyses on the data obtained and interpreted the study results. 
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Assistance was obtained with recruitment primarily from the oncologists and surgeons of 
the gynaecologic oncology team at Addenbrooke’s Hospital who initially approached 
potential participants with the invitation to take part and to speak to a researcher for more 
study details. Consultant radiologists from the Department of Radiology obtained image 
guided percutaneous biopsies from patients for use in research. The surgeons collected 
further, larger tissue specimens in theatre for research. Tissue samples were either frozen 
or fixed in paraffin at the Addenbrooke’s Tissue Bank by the Tissue Bank staff. Tissue bank 
staff also sectioned and stained tissue for histology and IHC as requested by the research 
team for the various MISSION-ovary imaging types. Additional IHC stains were performed by 
the Cancer Research UK, Cambridge Institute Histopathology and in situ hybridization core 
facility through the Brenton lab.  
Assistance with the operation of the MRI and PET scanners was obtained from 
radiographers and physicists at the Department of Radiology. Physicists from the 
department also assisted with the post-processing of imaging data including providing the 
Matlab code for the construction of diffusion parameter maps, sodium concentration maps, 
carbon-13 parameter maps and MRF maps. The respective individuals and their specific 
contributions are detailed in the relevant sections of the later Chapters of this dissertation 
which is divided according to imaging modality. 
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Chapter 2 
 
Ovarian cancer biology and current imaging 
techniques 
________________________________ 
 
2.1 Introduction 
In order to identify which patient demographics and biological properties of ovarian cancer 
it would be best to measure for comparison with each imaging technique studied here, it is 
essential to first understand ovarian cancer biology and the theory behind the imaging 
methods being employed. This chapter therefore summarises the current body of 
knowledge about ovarian cancer and the imaging techniques being explored in this PhD. The 
dissertation then goes on during subsequent chapters to look at each imaging technique in 
more detail and to provide results from human participants and preclinical experiments 
where relevant.  
 
2.2 Ovarian cancer origin and development 
Ovarian cancer like other cancers is caused by dysfunctions in the regulation of the cell cycle 
and other cellular processes, leading to uncontrolled replication and a build-up of excess 
cancer cells. The malignant transformation can include genetic changes and leads to cellular 
properties and behaviours that promote cancer progression such as a loss of contact 
inhibition between neighbouring cells, failure of the G1-S or G2 checkpoints of the cell cycle, 
an inability to enter the quiescent G0 phase after mitosis (13), metabolic alterations and 
angiogenesis. 
Multiple endogenous and environmental factors can contribute to an increased risk of 
ovarian cancer. Any factor that increases the rate of DNA replication in the ovaries or 
fallopian tube increases the risk that a DNA replication error can occur that may affect the 
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cell cycle and lead to cancer. For example, a greater number of ovulations increases the 
number of cell divisions that will have to occur in the ovaries to repair the corpus luteum 
after each ovulation. Hormones that stimulate growth and activity of the ovaries such as 
oestrogen can similarly cause an escalation of the risk for developing cancer. Germline 
genetic mutations and exposure to carcinogens that damage DNA are other common 
ovarian cancer risk factors. Table 2.1 gives a more comprehensive list of the risk factors for 
developing ovarian cancer. 
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Risk factors for the development of ovarian cancer 
 
1. Nulliparity 
2. TP53 mutation 
3. BRCA1 and BRCA2 germline mutations.  
4. Conditions like endometriosis, polycystic ovarian disease (PCOD) and obesity which 
increase the levels of hormones that stimulate ovarian cell proliferation. 
5. Early menarche or late menopause due to a larger number of ovulations during the 
lifetime.  
6. The use of hormone replacement therapy. 
7. A family history of cancers such as endometrial, colon or gastrointestinal cancers 
which may indicate the presence of syndromes that are associated with ovarian 
cancer like hereditary non-polyposis colorectal cancer or Lynch syndrome.  
8. Peutz–Jeghers syndrome. 
9. Icelandic, Hungarian, European Jewish and Ashkenazi Jewish descent. 
10. Environmental factors possibly related to diet and socio-economic class. Ovarian 
cancer is more common in industralised nations and has 30-40% higher prevalence in 
the white population when compared to the black and Hispanic populations of the 
USA. 
11. Older age up to 80 years after which risk declines possible due to hormonal changes 
associated with menopause. 
12. Breast cancer or a family history of breast cancer since many of the risk factors for 
breast cancer and ovarian cancer overlap. 
13. A family history of ovarian cancer. 
 
Table 2.1: Risk factors for developing ovarian cancer 
 
 
The risk of developing ovarian cancer can be reduced by any event that lessens the number 
of ovulations over an individual’s lifetime, by the avoidance of exposure to carcinogens, and 
by reduced exposure to hormones that cause ovarian growth (14). Some factors that protect 
against the development of ovarian cancer are given in Table 2.2. 
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Factors that protect against the development of ovarian cancer 
 
1. Use of the oral contraceptive pill especially the progesterone only pill. 
2. Breastfeeding. 
3. Pregnancy. 
4. Hysterectomy or tubal ligation since this prevents the passage of carcinogens through 
the fallopian tubes and to the ovaries. 
5. A low-fat diet. 
6. Sterility. 
 
Table 2.2: Protective factors against the development of ovarian cancer 
 
2.3 Ovarian cancer tumour classification 
Ovarian cancer develops most commonly from epithelial cells, germ cells or stroma cells in 
the female reproductive tract. The World Health Organization (WHO) classifies ovarian 
tumours into the following six categories: serous, mucinious, seromucinous, endometroid, 
clear cell and Brenner tumours (15). Tumours of epithelial origin make up around 90% of 
ovarian cancers and include the serous, clear cell, mucinous and Brenner tumours. Of the 
epithelial tumours, serous cancers are the most frequently occurring (16). Primary 
peritoneal cancer is similar to epithelial ovarian cancer and is treated in the same way. After 
epithelial tumours, the next most common cell of origin of ovarian cancers are the germ 
cells. Germ cell tumours include teratoma, dysgerminoma and choriocarcinoma (17). 
Stromal tumours occur less frequently and include fibroma, granulosa-theca cell tumours 
and metastatic lesions to the ovaries.  
Definitive diagnosis of ovarian cancer subtype is by histology and immunohistochemistry 
(IHC) staining. Serum tumour biomarkers and imaging also play a role clinically in 
determining cancer subtype, particularly in cases where biopsy is not possible. Diagnosis of 
disease subtype is essential for determining the optimal cancer treatment and is usually 
performed with a combination of histological analysis and imaging.  
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2.4 Ovarian cancer staging 
Ovarian cancer is staged according to the FIGO (Fédération Internationale de Gynécologie et 
d'Obstétrique) classification (18). There are four numbered stages of the disease. In Stage 1 
the cancer is confined to the ovaries. In Stage 2 there is spread of cancer to the pelvis or 
peritoneum but nowhere else in the abdomen. At Stage 3 the cancer has spread out of the 
pelvis or it has spread to the retroperitoneal lymph nodes in the abdomen. In Stage 4 
disease there are metastases to areas of the abdomen that are outside the peritoneum or 
the liver and spleen capsule. The stages of ovarian cancer can be further subdivided as 
outlined in Table 2.3. 
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Stage Description 
1a The cancer is inside only one ovary, which has an intact capsule. 
1b The cancer is present in both ovaries but still confined to the insides i.e. both 
capsules are intact. 
1c There is cancer in one or both ovaries as well as cancer on the surface of one or 
both ovaries. If no cancer is detected on the surface of an ovary a classification 
of Stage 1c can also be made if there are cancer cells in ascitic fluid, washings or 
spillage of the cancer at surgery. 
2a There is spread of cancer to the fallopian tubes or uterus. 
2b There is spread to other tissues in the pelvis not included in 2a such as the 
bladder or rectum. 
2c The cancer meets the criteria for 2b classification and there are cancer cells in 
abdominal ascitic fluid or washings. 
3a There is microscopic spread detectable in the peritoneum or cancer has spread 
to retroperitoneal lymph nodes. 
3b There are visible metastases to the peritoneum that are 2cm in diameter or less. 
3c Metastases larger than 2cm are present in the peritoneum, or metastases to 
liver or spleen capsule have occurred. 
4 The metastases are more distant and occur for example in the lung or liver 
parenchyma. Stage 4 disease may also be diagnosed if metastases are confirmed 
to extra abdominal lymph nodes or the inguinal lymph nodes. 
 
Table 2.3: Ovarian cancer staging 
 
 
Stage of disease at the time of diagnosis is currently an important predictor of outcome in 
ovarian cancer. Imaging of the chest, abdomen and pelvis with contrast enhanced CT is the 
usual method of disease staging. Stage also affects management as it has an influence on 
suitability for surgery and on the goals of chemotherapy administration which may for 
example be either therapeutic or palliative.  
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2.5 Ovarian cancer presentation 
The signs and symptoms of ovarian cancer can be very mild during the early stages of the 
disease but as it progresses lesions occupy more space and can spread to other parts of the 
body leading to more pronounced symptoms. Common presenting symptoms include 
discomfort in the lower abdomen, back or pelvis and a feeling of bloating and abdominal 
fullness (19). Pre-menopausal women sometimes experience irregular periods while post-
menopausal women can have vaginal bleeding. As the lesion becomes large enough to 
compress nearby organs, there may be increased urinary frequency, constipation, bowel 
involvement, indigestion, early satiety, pain during intercourse and a noticeable lump or 
swelling of the abdomen or pelvis. The constitutional symptoms of cancer develop at later 
stages and include weight loss, anorexia, tiredness, malaise and possibly symptoms in 
distant organ systems due to metastases.  
 
 
2.6 Serum tests 
There is currently no appropriate screening test for ovarian cancer. Because of the vague 
nature of early symptoms, patients often present at a late stage. The first investigation in 
the diagnosis is a physical examination. This may reveal a palpable mass in the pelvis or 
abdomen, ascites or symptoms in other organ systems such as respiratory or neurological 
problems if the cancer has already metastasized at presentation. 
The CA 125 (cancer antigen 125) blood test is performed if a suspicion of ovarian cancer has 
been raised from the history and examination of a patient. CA 125 is a protein that can be 
elevated in some types of ovarian cancer as well as other malignancies and several benign 
conditions. CA 125 is elevated in cancers of the ovaries, fallopian tubes, lungs, breast and 
gastrointestinal tract. It also goes up in endometriosis, leiomyoma, pelvic inflammatory 
disease (PID), salpingitis, menstruation, pregnancy, liver cirrhosis, pancreatitis, and 
inflammatory conditions of the abdomen. Serum CA 125 can also be used as a measure of 
treatment response and to screen for relapse in ovarian cancer patients (20). 
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When used to assess a patient with a pelvic mass, one study found an elevated CA 125 level 
above 30 U/ml had a sensitivity of 81% and specificity of 75% for detecting ovarian cancer 
(21). In patients with an average risk of ovarian cancer CA 125 is not considered to be a 
suitable screening test in isolation due to the high likelihood of falsely positive results that 
may lead to unnecessarily harmful and invasive procedures. Studies are ongoing to 
determine whether screening with CA 125 might be feasible in patients at a higher than 
average risk such as those with a strong family history of ovarian cancer or those who are 
known to have the BRCA mutation. Despite the difficulty in interpreting its value, CA 125 is 
still the most widely used blood marker for ovarian cancer and an important clinical 
question to address in the future would be the role of combining CA 125 with imaging or 
other novel technologies to assess for ovarian cancer more effectively in a multiparametric 
fashion. 
There are several other less specific markers of ovarian cancer. NICE (National Institute for 
Health and Care Excellence) recommends “In women under 40 with suspected ovarian 
cancer, measure levels of alpha fetoprotein (AFP) and beta human chorionic gonadotrophin 
(beta-hCG) as well as serum CA 125, to identify women who may not have epithelial ovarian 
cancer” (22). Serum measurement of circulating tumour DNA is an emerging test that may 
also find a role in diagnosis and monitoring of ovarian and other cancers (23). 
 
2.7 Diagnosis of ovarian cancer  
Ultrasound (US) is the initial imaging test recommended to investigate a pelvic or adnexal 
mass. If the US result is indeterminate and there is a strong suspicion of cancer, CT 
(computed tomography) or MRI (magnetic resonance imaging) can be undertaken to 
provide more information on the nature of the mass.  
On imaging, malignant lesions tend to be larger in size than benign lesions, they also display 
solid components of a heterogenous composition, contain internal structures if cystic, have 
lobulated shapes, contain areas of necrosis and blood vessels and can present with 
surrounding lymphadenopathy or peritoneal deposits visible on the imaging (24-26). MRI 
has been found to have a diagnostic accuracy of 88% to 93% at distinguishing between 
benign and malignant masses (27) and one study found that the sensitivity and specificity of 
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ultrasound for differentiating benign and malignant ovarian masses were 91% and 96% 
respectively (26). 
If the ovarian mass is in a location that is amenable to biopsy, a histological diagnosis can be 
attempted. In cases where no mass is seen on imaging, abdominal paracentesis is 
sometimes carried out to look for cancer cells in ascitic fluid. Definitive diagnosis of ovarian 
cancer can only be made through cytology or histology performed on specimen samples 
obtained from surgery or biopsy. After a diagnosis of cancer has been confirmed, a staging 
CT of the chest, abdomen and pelvis is usually performed. 
In cases where blood tests and imaging investigations do not lead to a clear diagnosis of 
ovarian cancer, risk scoring can be applied to determine the likelihood that the patient has 
ovarian cancer. The most widely used method of risk scoring in suspected ovarian cancer is 
the RMI (risk of malignancy index). RMI is calculated as follows: 
 
RMI = ultrasound score x menopausal status x CA-125 level in U/ml 
 
The ultrasound score is determined from the number of abnormalities found on US scan. An 
abnormality is defined as the presence of any of the following 5 findings: multilocular cysts, 
solid areas of malignancy, ascites, abdominal metastases and bilateral ovarian cysts or 
masses.  
 
Zero abnormalities give an ultrasound score of 0 
One abnormality gives an ultrasound score of 1 
Two or more abnormalities give and ultrasound score of 3 
 
For menopausal status: 
Pre-menopausal women are given a menopausal status score of 1 
Post-menopausal women are given a menopausal status score of 3 
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An RMI score over 200 is considered to indicate a high risk of malignancy (28). 
The risk of ovarian cancer algorithm (ROCA) is an alternative scoring method that assesses 
the probability a patient has ovarian cancer. ROCA can be applied in lower risk cases prior to 
imaging and follows the CA-125 or other serum biomarker levels over time with serial blood 
tests. ROCA scoring recommends imaging when the calculated risk from serum biomarkers 
is high (29). 
 
2.8 Ovarian cancer treatment 
Treatment options for ovarian cancer include surgery and chemotherapy. The optimal 
treatment strategy for an individual patient depends on the disease subtype, stage at 
diagnosis and any existing co-morbidities. The type of surgery undertaken is usually 
determined by the extent and location of disease, particularly the relationship and proximity 
to surrounding structures like blood vessels that may be affected or damaged during an 
operation. In addition to removal of the pelvic mass, surgery usually involves lymph node 
biopsy, omentectomy, hysterectomy and bilateral salpingo-oophorectomy, unless there is a 
desire to retain fertility. When a patient is not suitable to undergo surgery or when surgery 
alone is not enough to remove all of the disease, chemotherapy treatment can also be 
applied. The majority of chemotherapy drugs in ovarian cancer are prescribed for epithelial 
ovarian cancer, which is most commonly high grade serous ovarian cancer. 
For advanced ovarian cancer it is still unclear whether the best treatment strategy is primary 
debulking surgery followed by chemotherapy or neoadjuvant chemotherapy (NACT) 
followed by interval debulking surgery. When surgery leaves less than 1cm maximal 
diameter of residual disease it is considered optimal debulking (30). Primary debulking 
surgery attempts to remove cancerous tissue as the first therapeutic intervention following 
diagnosis. NACT on the other hand is chemotherapy given prior to surgical intervention. 
After NACT the patient is imaged to identify the current location of cancer and surgery is 
then performed to remove remaining cancer and is referred to as interval debulking surgery 
(IDS). IDS may be followed by further chemotherapy and surgery. 
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For ovarian tumour types that are known to be poorly chemosensitive, primary debulking 
surgery is a better option than NACT. For patients with poor performance status who may 
not be fit enough to withstand the insult of a major operation, NACT to reduce the tumour 
burden followed by interval debulking surgery is often a better option (31). The treatment 
for each individual patient is decided by a multidisciplinary team (MDT) comprising 
oncologists, surgeons, radiologists, histopathologists and allied health professionals. 
 
2.9 High grade serous ovarian cancer 
Serous ovarian cancer may be classified as low grade, high grade or indeterminate grade 
based on the nuclear grade of the cancer cells, with nuclear grade 1 classified as low grade, 
nuclear grade 2 classified as indeterminate and nuclear grade 3 classified as high grade. 
Recent studies have suggested that indeterminate grade may not represent a truly separate 
classification and some clinicians prefer to use a two tier classification comprised of only low 
and high grade (32).  
Tumour grades are determined histologically according to the appearances of cells under 
light microscopy as follows:  
 
GB: borderline cancer - cells appear borderline cancerous 
G1: low grade - cells are well differentiated. 
G2: intermediate grade - cells are moderately differentiated. 
G3: high grade - cells are poorly differentiated.  
GX: grade cannot be evaluated. 
 
Mutations in the KRAS, BRAF and ERBB2 genes are characteristics of low grade serous 
ovarian cancer (LGSOC) whereas TP53 mutation is characteristic of HGSOC. The molecular 
genetic profiling and the behaviour of intermediate grade serous ovarian cancer is almost 
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the same as HGSOC and for this reason intermediate grade serous ovarian cancer is often 
classified as HGSOC (33). HGSOC affects older women in the peri-menopausal age range 
while LGSOC is more common in pre-menopausal women (34). HGSOC is more sensitive to 
chemotherapy while LGSOC is less responsive (35). The response of HGSOC to 
chemotherapy and the relationship of response to DKI is explored further in Chapter 3.    
High grade serous ovarian cancer (HGSOC) is the most clinically important type of ovarian 
cancer due to its high prevalence and poor prognosis. LGSOC has a better outcome and 
distinguishing between these grades is therefore clinically important in planning treatment. 
Reasons for the poor outcomes in HGSOC patients include the aggressive nature of the 
disease, the late stage at which the disease is typically diagnosed and the lack of highly 
effective therapies. 
HGSOC originates in the secretory cells of the fallopian tubes and metastasizes to the 
ovaries and peritoneum early on in its course. The stage of the disease at which diagnosis is 
confirmed has a significant impact on survival (36, 37).  Approximately 90% of women who 
are diagnosed at FIGO stage 1 survive for five years. With diagnosis at stage 2 the 5-year 
survival decreases to 40%, at stage 3 survival is 20% and less than 5% for those diagnosed in 
stage 4 are alive after 5 years (14, 38). Currently, 70% of women with HGSOC are diagnosed 
at stages 3 or 4 resulting in overall statistics of less than half of women with HGSOC 
surviving for 5 years and around 75% dying within 10 years of the discovery that they have 
the disease.  
For HGSOC, debulking surgery is performed either before or after chemotherapy. Patients 
with advanced disease may have several episodes of interval debulking surgery during the 
course of their chemotherapy treatment. Even with an optimal treatment regimen however, 
the relapse rate at six months in HGSOC patients is still around 30% and overall recurrence 
rates following chemotherapy and negative “second look” laparotomy are around 50% at 10 
years (39). First-line chemotherapy treatment for HGSOC has not changed in the last 30 
years and remains a combination of a platinum-based drug and a taxane. However, in 
relapsed disease a wider variety of drugs is available. The most common treatment in the 
UK for relapsed HGSOC is gemcitabine plus carboplatin but clinical recommendations also 
suggest consideration of doxorubicin, topotecan and trabectedin for advanced recurrent 
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disease and etoposide and cyclophosphamide as options for platinum resistant cases. Other 
drugs that have shown efficacy in the treatment of ovarian cancer but are still currently 
undergoing clinical trial evaluations include the VEGF (vascular endothelial growth factor) 
inhibitor bevacizumab, PARP (poly ADP-ribose polymerase) inhibitors and immunotherapy-
based treatments. 
 
2.10 Post-diagnosis imaging in ovarian cancer management 
 
Although ultrasound is the first line imaging modality for assessing an adnexal mass, after 
the diagnosis of ovarian cancer has been made, it is necessary to also investigate 
neighbouring organs and bones for disease spread. In this role, CT is more suitable than US, 
as US is unable to adequately image some abdominal regions such as deeply placed tissue. 
CT is also required to assess the lungs, as metastases to the lungs often indicate inoperable 
disease that should be treated with chemotherapy alone.  
In those patients being considered for surgical management, the identification of peritoneal 
spread and of lesions in the vicinity of the liver and spleen as well as mesenteric and bowel 
involvement are all important for surgical planning as these can affect outcome and some 
aspects of the surgery such as the need for bowel resection and the creation of a stoma 
(40). CT is the most commonly used imaging modality in surgical planning with MRI and PET 
occasionally also used to provide complementary information in cases where CT findings are 
indeterminate. 
In those patients undergoing NACT treatment CT scanning is performed again after the cycle 
of chemotherapy just before surgery. This is done to monitor the changes caused by the 
chemotherapy and to plan surgery accordingly.  
After surgery, clinic appointments are used to monitor for relapse. Patients are assessed for 
symptoms, have serum CA 125 measured and sometimes imaging is performed. There is 
variation in follow-up strategies across cancer networks in the UK (41). The majority of 
centers report offering follow-up appointments every 3 months for the first 2 years after 
treatment followed by every 6 months for the next 2 years (42). In relapsed ovarian cancer 
where there are a greater number of chemotherapy and anti-cancer drug options available, 
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the monitoring of response with CA 125 and CT imaging can be used to inform therapeutic 
choices.    
 
2.11 Magnetic resonance imaging in ovarian cancer 
Magnetic resonance imaging is able to offer a range of different contrasts that reflect 
diverse tissue properties. HGSOC is a heterogenous disease and methods of non-invasively 
probing tissue structure and function can uncover details about tumours that it would not 
be possible to detect with point biopsy samples alone. Imaging also has the advantage over 
histology in tumour evaluation that it causes minimal disturbance to the tissue 
environment. 
Ovarian cancer is a difficult disease to image due to the location of the lesions in the pelvis 
and abdomen and the generally poor performance status of women with the condition. 
These challenges have contributed to many promising imaging techniques not being fully 
evaluated in ovarian cancer and there is consequently still significant room for 
improvements in clinical imaging tests. This PhD has applied novel and emerging imaging 
techniques to the study of ovarian cancer, with a focus on identifying specific clinical 
applications for high grade serous ovarian cancer. The methods explored include diffusion 
kurtosis imaging to investigate tissue heterogenity, sodium MRI to measure tumour 
cellularity, magnetization transfer imaging to assess the extracellular matrix, metabolic 
imaging with hyperpolarized carbon-13 MRI and positron emission tomography (PET), and 
magnetic resonance fingerprinting to map tumour relaxation parameters. The remaining 
sections in this chapter introduce these imaging techniques and their use to investigate 
ovarian cancer while subsequent chapters describe in greater detail the human results 
obtained for each imaging technique.  
 
2.12 Diffusion weighted imaging in cancer 
 
Diffusion weighted imaging (DWI) applies magnetic-field gradient pulses to sensitize the 
imaging signal to the microscopic motion of water molecules. In areas where there is 
minimal movement or diffusion of water, the net effect of these gradient pulses is small and 
the final signal recorded has a high value. In areas of tissue where there is a large amount of 
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diffusion, the movement causes partial dephasing of magnetizations and leaves a smaller 
residual signal. The strength of the diffusion sensitization in DWI is quantified by the b-
value. DWI enjoys widespread use in oncology. In cancers increased cellularity obstructs the 
free movement of water and causes the cancerous lesions to appear brighter than 
surrounding healthy tissue. 
For clinical use, it is typical to calculate an apparent diffusion coefficient (ADC) map from 
diffusion weighted images under the assumption that the water molecules diffuse in a 
Gaussian fashion. The ADC values for each voxel are found by fitting the signal strengths and 
b-values of the diffusion weighted images to the mono-exponential equation given below. 
 
S(b) = S0·exp (−b· ADC) 
 
where S0 is the DWI signal in the voxel under consideration with no diffusion sensitization 
(at b-value = 0 s/mm2) and S(b) is the signal strength at the voxel on the DWI image taken 
with a b-value of b. 
Diffusion kurtosis imaging (DKI) is a new method of diffusion modelling that includes fitting 
of the diffusion weighted MRI signal to the second term in the Taylor expansion of the 
expression relating diffusion weighted signal intensity to b-value. Inclusion of the second 
term in this expansion gives information on kurtosis of the signal (43). The use of DKI in 
ovarian cancer patients is explored further in Chapter 3. 
 
2.13 Sodium imaging and physiological alterations in cancer 
Sodium concentrations in cancer can be affected by changes in ion transport, perfusion and 
cellularity among other biological properties of tissue (44). MRI has the ability to quantify 
total tissue sodium concentration and intracellular sodium concentration due to a 
difference in relaxation times of intracellular and extracellular sodium (45, 46). 
Quantification of sodium with MRI may therefore provide information on several 
physiological processes in cancer (47).   
(2.1) 
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In healthy tissue, the concentration of sodium differs between the intracellular and 
extracellular spaces. The exact values of sodium concentration in each compartment 
depends on tissue type and the physiological state of the tissue, but in most cases 
intracellular sodium concentration is around 5 to 15 mM (48) and extracellular sodium 
concentration is 135 to 150 mM. Higher cellularity increases the proportion of intracellular 
space while vascularity and oedema increase the extracellular volume. Tissue sodium 
concentration (TSC) is an average of the intracellular and extracellular sodium 
concentrations weighted according to the volumes of these two spaces. 
It is energetically very favourable for the extracellular sodium ions to move intracellularly 
down their concentration gradient. The difference between the intracellular and 
extracellular sodium environments must therefore be actively maintained. The phospholipid 
bilayer of the cell membrane is selectively permeable to sodium and only allows a small 
amount of sodium to enter the cell by passive diffusion, the majority of sodium that moves 
across the cell membrane does so in a regulated fashion through specialized transporters.  
The accumulation of sodium intracellularly must be counteracted to maintain normal 
cellular homeostasis. For most tissues the Na+/K+-ATPase pump also known as the sodium-
potassium pump is the dominant contributor to the removal of intracellular sodium and the 
maintenance of a steady-state intracellular sodium concentration (49). The sodium-
potassium pump uses the hydrolysis ATP into ADP and inorganic phosphate (Pi) to provide 
the energy to drive 3 Na+ ions out of the cell in exchange for every 2 K+ ions that it brings 
into the cell. The sodium pump is extremely energy intensive as it must overcome the 
powerful intracellular driving forces acting on the sodium ions. This leads to the sodium-
potassium pump’s consuming of a large proportion of the energy available to tissue. Under 
normal circumstances the sodium-potassium pump activity is not limited by ATP availability 
but in anoxic conditions tissue ATP levels have been shown to be insufficient for the pump 
to function (50) and both the ion transport and hydrolytic activity of the sodium-potassium 
pump are suppressed when in hypoxic and hyperoxic states (51, 52). The sodium-potassium 
pump is therefore more oxygen sensitive than it is responsive to ATP concentration. 
Cancer tissue is often hypoxic and energy resources are also diverted away from healthy 
physiological processes and towards growth, replication and expansion. The rate of 
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metabolism of glucose via pathways like oxidative phosphorylation which produce the 
maximum yield of ATP is reduced in cancer and glucose use is instead shifted towards other 
processes like the manufacture of nucleotides, lipids and amino acids (53, 54) needed for 
growth. The incomplete breakdown and trapping of glucose as other molecules within 
cancers has been demonstrated previously on 18F-fluorodeoxyglucose positron emission 
tomography (18F-FDG-PET) imaging (55, 56). 
The growth of cancer fuelled by these metabolic changes may be so rapid that it can 
eventually outstrip the tumour’s blood supply leading to poor perfusion and worsening 
hypoxia. Over time tumours can become oxygen and energy deficient to the point where 
necrosis occurs (57). VEGF (vascular endothelial growth factor) activity is usually increased 
in tumours that are hypoxic to help compensate for the reduced blood supply by stimulating 
blood vessel growth. The presence of VEGF is a poor prognostic marker in certain cancers 
(58-60). VEGF additionally contributes to blood vessel porosity and tissue oedema (61) 
which increases the relative amount of high sodium concentration extracellular fluid and 
therefore overall tissue sodium concentration even further.   
In hypoxic tissue, the sodium-potassium pump activity decreases permitting the 
accumulation of sodium intracellularly. This sodium draws water with it by osmosis and 
contributes to cell swelling (62, 63). The accumulation of sodium intracellularly is one of the 
precursors to cell death (64) and measurement of intracellular sodium may therefore serve 
as an early biomarker for both hypoxia induced necrosis and cell death in response to 
treatments like chemotherapy.  
The effect of cancer formation on the intracellular sodium concentration may be more 
pronounced in the areas of a tumour with the most hypoxia and the poorest perfusion. If 
this is the case, it would mean that quantification of the intracellular sodium concentration 
in cancer could provide information on the extent of the shift of a cancerous tissue towards 
growth and expansion and therefore relate to the aggressiveness of the tumour.  
Apart from metabolism, changes to the integrity of the cell membrane and changes in 
cellularity with cancer formation may also affect the distribution of sodium. Porous or 
completely degenerated membranes in dying or necrotic cells increase the freedom of 
movement of sodium between the intracellular and extracellular compartments and may 
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lead to equilibration of concentrations. Changes in the ratio of intracellular to extracellular 
space also occur with the denser cell packing of tumours and with the accumulation of 
extracellular fluid from cancer induced inflammation and oedema. 
The sodium nucleus is magnetic resonance active and endogenous nuclei can be imaged 
with MRI by applying radiofrequency radiation of the wavelength at which sodium 
resonates. This requires special transmit and receive hardware that can produce the 
appropriate RF pulse and detect the sodium MRI signal. For sodium MRI, the scanner being 
used must also be capable of multi-nuclear imaging. Multi-nuclear scanners and sodium 
transmit and receive coils are available commercially. In Chapter 4 of this PhD results from 
sodium imaging in ovarian cancer patients are presented. 
 
2.14 Magnetization transfer imaging in cancer 
Water molecules in biological systems can exist either as free molecules or bound to 
macromolecules like proteins and lipids. Bound water is also known as structured water and 
can form hydration layers of restricted water motion that extend around surfaces like cell 
membranes for several molecular diameters (65). The macromolecules to which bound 
water attaches cause a broadening in the range of frequencies at which water can absorb 
magnetization, whereas free water only responds over a much narrower range of 
magnetization frequencies. 
In magnetization transfer (MT) imaging an “off-resonant” radiofrequency (RF) pulse is used 
to preferentially saturate bound water. Some of this saturation is transferred to the free 
water molecule pool either through magnetic coupling between free and bound water 
molecules or by direct molecular exchange (66). A magnetization transfer ratio (MTR) can 
then be derived that provides information on the macromolecules present in a tissue. MT 
imaging uses the large visible free water pool to report on the much smaller bound water 
pool and consequently, MT delivers an alternative form of contrast to T1, T2, and proton 
density weighted imaging. MT imaging reflects the degree to which saturation exchange 
occurs between the free and bound states which is a form of spin-lattice relaxation (67).  
In cancer, there is remodelling of extracellular matrix macromolecules. MT imaging in cancer 
may provide information on these changes. Changes in tumour stroma relate to 
39 
 
invasiveness and prognosis and imaging of the matrix of cancers may thus have important 
implications for treatments and outcomes in oncology. 
For some solid tumours such as prostate cancer, MTR has been found to be higher in cancer 
compared to normal tissue (68). In other tumours such as glioma, MTR decreases compared 
to normal brain, as the central nervous tissue macromolecular myelin concentration drops 
in several cerebral disease processes including cancer (69). In breast cancer both increases 
and decreases in MTR relative to benign tissue have been found which may relate to 
differences in the extracellular macromolecular tissue (70, 71) and in hepatic malignancies 
an MTR similar to that of normal liver has been noted in one study (72). Recently a small 
number of studies have also found use for magnetization transfer imaging in assessing the 
response of some cancers to therapy (73, 74). 
Despite its extensive use in previous studies, the specific macromolecules responsible for 
changes in MTR with malignancy have never been identified. The high cellular proliferation 
of cancers may contribute to an increase in macromolecule content but the destruction of 
the surrounding tissue by cancer may simultaneously lead to a decrease in available water 
binding sites. The comparison of MTR with tissue macromolecule measurements could 
therefore provide valuable information on the tumour microenvironment that has not yet 
been identified. The relationship of tumour macromolecules to MT imaging is compared 
with ovarian cancer in Chapter 6 of this dissertation.  
 
2.15 Hyperpolarized carbon-13 MRI 
Hyperpolarized carbon-13 MRI (HP 13C-MRI) is a new imaging technique that can provide 
unique metabolic information about cancer. HP 13C-MRI involves the use of molecules 
labelled with 13C that have undergone an alignment of their nuclear spins that significantly 
increases the MRI signal that can be detected: this allows an injected molecule and its 
biochemical reactions in tissue to be imaged in vivo to provide real time information on the 
metabolism of tissue and the activity of enzymes in the tumour environment (75). 
Clinical HP 13C-MRI is currently restricted to the imaging of hyperpolarized 13C labelled 
pyruvate metabolism. This is due to the favourable physical and chemical properties of 
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pyruvate for hyperpolarization and the fact that pyruvate is central to a number of 
important cellular biochemical reactions in normal tissue and in tumours.  
The term hyperpolarization refers to an array of techniques that increase the proportion of 
nuclei aligned with the main MR magnetic field. Historically, a variety of methods have been 
used to increase polarization for metabolic imaging. One of these is dynamic nuclear 
polarization (DNP). DNP involves the cooling of the carbon-13 labelled molecule close to 
absolute zero (~1 K) in magnetic field (3.35-5 T) which causes electrons to be almost fully 
polarized. The sample is then irradiated with microwave radiation to transfer the 
polarization from surrounding electrons to the carbon-13 nuclei. In 2003 a breakthrough 
occurred using this method when it was demonstrated that it could increase the MR signal-
to-noise ratio of carbon-13 by more than 10,000-fold and the frozen sample could 
subsequently be dissoluted into the liquid form and warmed so that it could be injected into 
biological systems while maintaining polarization levels with a half-life of around 60 s in 
vitro (76). These discoveries have now led to the possibility of using molecules labelled with 
carbon-13 to quantify and image tumour metabolism in vivo in unprecedented detail.  
For clinical hyperpolarized carbon-13 (HP C-13) imaging a special setup is required where 
the MRI scanner and hyperpolarizer are in separate rooms to minimize interference 
between their magnetic fields. After dissolution in the hyperpolarizer, the hyperpolarized 
sample must undergo quality control (QC) checks to ensure it is safe for injection into a 
human. This is done by spectrophotometry to measure parameters such as concentration 
and pH. After the QC check, the sample is rapidly moved into the room with the MRI 
scanner and loaded into a syringe pump to be injected into the patient. Like with sodium 
imaging, a dedicated coil sensitive to carbon-13 is required to detect the signal and the 
scanner must have multi-nuclear capabilities. Due to the low signal strength even after 
hyperpolarization, a 3T or more powerful field strength scanner is required to produce 
images of sufficient signal-to-noise ratio to create meaningful images. The rapid decay of 
the C-13 signal also requires that a fast acquisition pulse sequence is used to perform 
imaging before the majority of the signal disappears. This is explained further in Chapter 7 
and a case report of a benign ovarian tumour is presented in Chapter 9.  
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2.16 18F-FDG-PET imaging 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) utilises 2-deoxy-2-
(18F)fluoro-D-glucose, also called 18F-fluorodeoxyglucose (18F-FDG) to image tissue 
metabolism. 18F-FDG is an analogue of glucose that is taken up by cells where it is trapped in 
the intracellular space following phosphorylation by the enzyme hexokinase as 18F-FDG-6-
phosphate, which cannot be metabolised further by glycolysis due to the lack of a 2-
hydroxyl group. Fluorine-18 (18F) undergoes radioactive decay with a half-life of around 110 
minutes mostly by positron emission but also by electron capture to produce oxygen-18 
(18O). 18F decay by positron emission follows the reaction below: 
 
18F              18O + e+ + ve 
 
where e+ represents the positron – the positively charged anti-particle of an electron - and 
νe denotes the neutrino emitted during decay. The conversion of fluorine-18 into oxygen-18 
generates the 2-hydroxyl group needed for glycolysis and allows the tracer to be 
metabolised in a manner similar to glucose. 
Positron emission decay is also known as positive beta (β+) decay. The positron emitted on 
β+ decay travels through tissue until it encounters an electron (e-) at which point both the 
positron and the electron undergo annihilation, producing two equivalent photons of 
approximately 511 keV energy that move in approximately opposite directions. The 
annihilation photons are detected by an array of scintillator detectors located on the 
scanner and the positions and times at which these are detected is used to identify the 
point of origin of the annihilation event. Tissues exhibiting higher 18F-FDG transport and 
higher rates of 18F-FDG phosphorylation by hexokinase display increased 18F-FDG-PET signal. 
PET can provide a direct measurement of 18F-FDG radioactivity concentration (Bq/mL) in 
vivo, nevertheless it is the relative tissue uptake of 18F-FDG that is utilised in clinical practice 
to facilitate comparisons between patients. The two most significant sources of variation 
that occur in 18F-FDG uptake in patients are due to the amount of injected 18F-FDG activity 
and the patient’s size. To account for these the standardized uptake value (SUV) is used 
(2.2) 
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clinically to provide a measure of the relative uptake of 18F-FDG in tissues (77). The SUV of 
an area in an image is the ratio of the concentration of radioactivity in this area divided by 
the radioactivity injected into the patient normalised by body weight. Expressed as an 
equation: 
 
SUV = 	Radioactivity	concentration	in	region	of	interest	(Bq/mL)Injected	activity	(Bq)	/	Body	weight	(g)  
 
SUVmax is the maximum SUV voxel value within a region of interest and is a routine clinical 
tool for interpreting PET images. Other metrics like SUL (Standardized Uptake normalised to 
lean body mass) may offer more accurate estimates of uptake but are not yet as widely used 
as SUV, reference data for the interpretation of SUL values are therefore not as readily 
available as SUV making SUV a more accessible and recognizable tool for scientific research 
and the implementation of findings among clinicians. The measured SUV on imaging is 
affected by serum glucose concentration, GLUT transporter expression, liver metabolism, 
blood flow, renal excretion of 18F-FDG and the time point of imaging. To help address the 
time-point dependence and inaccurate normalisations of tracer availability with SUV, kinetic 
modelling approaches can be used on dynamic 18F-FDG data (78).  
SUVmax is higher in cancerous tissue because of an increase in metabolic activity, GLUT 
expression and greater activity of mitochondrial hexokinase enzyme. 18F-FDG -PET in ovarian 
cancer is sometimes used clinically when lesions are difficult to evaluate on other types of 
imaging or when there is a need to detect metastatic disease for staging (79). SUVmax has 
also been used in the context of clinical trials for treatment response monitoring and the 
detection of ovarian cancer recurrence (80, 81). In this PhD, FDG-PET is used as a 
comparison with HP 13C-MRI with the findings detailed in Chapter 9. 
 
2.17 Magnetic resonance fingerprinting 
Magnetic resonance fingerprinting (MRF) is an acquisition technique than can rapidly 
produce quantitative maps of multiple magnetic resonance parameters.  Quantitative maps 
(2.3) 
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of MRI parameters have higher repeatability and reproducibility than weighted images and 
their use could improve data comparisons across different centres and scanners and 
therefore improve diagnostic reader consistency. The T1, T2 and proton density maps of MRF 
can also be used to construct images of multiple weightings after the imaging session and 
provide varied forms of tissue contrast for diagnostic use without occupying the MRI 
scanners of a hospital radiology department. 
Conventional acquisitions of T1, T2 and proton density maps are time consuming and 
impractical in routine clinical practice. MRF can generate quantitative parameter maps in 
shorter scan times using ultra-short TE (UTE) techniques (9) and only one signal acquisition 
which also makes MRF relatively insensitive to motion. 
MRF uses a pseudorandom simulation of flip angle, repetition time (TR) and other imaging 
parameters to create a signal evolution pattern or “fingerprint” in each voxel that depends 
on the tissue types in that voxel and the intrinsic MR properties of those tissues such as the 
T1, T2 and proton density. The MR signal pattern that is detected can then be mapped to a 
dictionary to output synthetic maps of the MR parameters and to produce weighted images. 
The first published data on MRF in ovarian cancer was acquired a part of this PhD with 
MISSION-ovary patients and is described in Chapter 10. 
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Chapter 3 
Diffusion kurtosis imaging in ovarian cancer 
________________________________ 
 
 
3.1 Background 
The best outcomes in high grade serous ovarian cancer (HGSOC) occur when treatment is 
with a combination of surgery and chemotherapy (82). The initiation of chemotherapy in 
ovarian cancer patients however usually requires a definite diagnosis of the epithelial 
subtype as chemotherapy is associated with significant side effects and its use would not be 
justified in cases of less malignant ovarian lesions.  
Currently, there is no imaging or serum biomarker test that can reliably separate HGSOC 
from other ovarian cancers in patients who present with a suspicious pelvic mass. Diagnosis 
of HGSOC therefore relies on biopsy sampling and histopathological analysis of tissue 
including immunohistochemistry. Unfortunately, in some patients, the ovarian cancer 
presents in an anatomical location that is not amenable to any form of image guided 
percutaneous needle biopsy, either because the cancer deposits are too deep within the 
abdomen and pelvis or are in close proximity to high risk structures that could be damaged 
by the trauma of biopsy. Patients with these problems are often sent for a surgical 
procedure to extract diagnostic tissue samples which in some cases can include removal of 
additional organs like the uterus, omentum, fallopian tubes and ovaries to avoid the need 
for future operations.  
Biopsy whether performed percutaneously or by an open procedure is invasive and carries 
with it risks of discomfort, bruising, bleeding, and infection. Needle biopsy samples may also 
extract inadequate amounts of tissue or sample the incorrect area, sometimes missing the 
cancerous lesion entirely. Even more concerning is the fact that biopsies do not represent 
the whole ovarian lesion as each sample is taken from only one point. In the most malignant 
tumours like HGSOC, tissue heterogeneity is a prominent feature meaning that different 
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areas of the tumour have a distinct biochemical, histological and genetic composition (83, 
84). As a consequence, biopsy with histology although considered the gold-standard 
diagnostic test can still misclassify ovarian lesions and lead to incorrect or suboptimal 
treatment of HGSOC. 
The first line chemotherapy choice for HGSOC is a platinum-based drug together with a 
taxane (85), both of which inhibit cell division. This combination however, has a complete 
remission rate of only around 50% (85, 86). Newer targeted therapies based around DNA 
damage repair inhibition (87, 88), vascular growth factor inhibition (88) and immune 
checkpoint inhibition (89) are now being developed that may provide alternative treatment 
options to HGSOC patients in the future. With the availability of new therapies, there is an 
increasing need for methods to both predict and detect the response to treatment in 
HGSOC at the earliest timepoints possible, so that the best personalized therapies can be 
selected for individual patients. 
Diffusion weighted imaging (DWI) is a reproducible imaging method (90, 91) that uses 
Gaussian modelling and has previously been shown to identify early treatment response in 
HGSOC by reporting on the cytotoxic effect of platinum-based chemotherapy (92). This 
study evaluated an extended version of diffusion modelling in MRI, diffusion kurtosis 
imaging (DKI), as a predictor of response before the initiation of treatment.  
The Gaussian or mono-exponential model of diffusion assumes that the main obstructions 
to diffusion are evenly distributed and restrict diffusion uniformly. In tissue it is the cells, 
organelles within cells, extracellular matrix structures and fibers such a myelin sheets in 
brain that are the main obstacles to diffusion. The complexity of microstructure and the 
complexity of the distribution of cells increases in cancer compared to healthy tissue and 
imparts a positive kurtosis to the Gaussian pattern of diffusion. High heterogeneity in the 
composition and spatial distribution of cancer cells means that the ADC maps currently used 
for clinical practice may inaccurately represent the diffusion of water molecules for cancers. 
To create quantitative maps, DKI employs a bi-exponential model that makes use of the 
second term in the Taylor series expansion of the DWI signal to fit each voxel in an image 
(93). The additional exponential term relates to the kurtosis caused by the tissue to the 
diffusion signal. With imaging of higher diffusion weighting, the kurtosis effect on diffusion 
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becomes more apparent.  DKI therefore requires the inclusion of DWI images of high b-
value (94). DKI produces maps of two parameters, Dapp (apparent diffusion) and Kapp 
(apparent kurtosis). In DKI, the diffusion weighted images are fit to Equation (3.1) below.  
 
S(b) = S0·exp (−b· Dapp + 1/6 · b2· Dapp2 · Kapp) 
 
The nuclear protein Ki-67 is a marker of proliferation and tissue heterogeneity and has 
displayed a correlation with DKI in several malignancies, including ovarian cancer (95-97). 
Although Ki-67 is a marker of proliferation it may also serve as a marker of tissue 
heterogeneity as more proliferative tissues are likely to also be more heterogenous. Ki-67 
has also been shown to identify cancers that are sensitive to chemotherapeutic agents that 
target proliferating cells (98, 99). These previous findings support the hypothesis that DKI 
could predict the response of HGSOC to chemotherapy agents that function by inhibiting cell 
division and there is already some evidence to support this in nasopharyngeal cancer (100). 
The work here assesses the ability of DKI to predict the response of HGSOC in patients 
undergoing three cycles of standard of care neoadjuvant chemotherapy (NACT) treatment 
for the first time. Results from this chapter have been published in the journal Scientific 
Reports (101).  
 
3.2 Methods 
Ethical approval for this study was obtained from a local Research Ethics Committee (South 
Cambridge REC) as part of the MISSION-ovary study and all study related procedures were 
performed with the written informed consent of participants. This study was carried out in 
accordance with the research ethics guidelines outlined in the 1965 Declaration of Helsinki.  
 
Imaging 
A 3T MRI scanner (Discovery MR750, GE Healthcare, Waukesha WI) and a 32-channel 
cardiac array coil were used to perform DWI and T2-weighted imaging on participants 
(3.1) 
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between one and seven days (median four days) before the start of chemotherapy 
treatment. A spectro-spatial excitation pulse was used to produce water selective excitation 
and 20mg of intravenous hyoscine butylbromide was given prior to imaging to reduce bowel 
motion. Full scan parameters are listed in Table 3.1. 
 
Table of DKI study imaging parameters 
 
Imaging parameter T2-weighted  Diffusion weighted imaging 
  TR 4000 ms 6000 ms 
  TE 91.1 ms 94 ms 
  flip angle 90° 90° 
  slice thickness 6 mm 6 mm 
  FoV 34.0 cm × 29.9 
cm 
34.0 cm × 29.9 cm 
  matrix 256 x 256 128 × 112 
  signal averages 8 4 
  parallel imaging - ASSET, factor 2 
  bandwidth 99.8 kHz ± 142 kHz 
  total scan time 1 min 54 sec 7 min 42 s 
  b-values - 100, 500, 900, 1300 and 1700 s/mm2  
 
Table 3.1: T2-weighted and diffusion imaging parameters. TR = repetition time, TE = echo 
time, FoV = field of view. 
 
Apparent diffusion (Dapp), in mm2/s and apparent kurtosis (Kapp), unitless maps were 
generated by Dr Andrew Priest from the Cambridge Department of Radiology with in-house 
software written in MATLAB R2018a (The MathWorks Inc., Natick, MA), by performing a 
pixel-wise non-linear fit to the bi-exponential diffusion kurtosis model described in equation 
3.1. Apparent diffusion coefficient (ADC) values, in mm2/s were also calculated with 
MATLAB using conventional mono-exponential Gaussian diffusion modelling from the 
images with b-values of 100, 500 and 900 s/mm2. Regions of interest (ROIs) were drawn on 
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the Dapp maps with OsiriX (version 3.8.1, Pixmeo, Geneva, Switzerland) around all solid 
cancerous lesion with care taken to exclude cystic and necrotic regions. ROIs were imported 
onto the ADC and Kapp maps, which were assumed to be co-registered as they were derived 
from the same set of DWI images. ROIs were reviewed by a radiologist, with 8 years of 
attending experience in oncological imaging and who was kept blind to treatment response 
and tissue analysis results. For each patient all tumour ROIs present in the abdomen and 
pelvis were combined into a single volume of interest (VOI). Intraobserver and interobserver 
variability were also assessed with a second set of ROIs drawn by myself. 
 
Response evaluation 
Response to NACT was assessed according to Response Evaluation Criteria In Solid Tumours 
(RECIST) criteria version 1.1 (102), using contrast enhanced CT scans. These were a baseline 
CT scan before the initiation of chemotherapy and a second CT scan up to one week after 
the third cycle of chemotherapy. The team of attending gynaecologic radiologists 
performing evaluations of response were blinded to MRI and tissue analysis results. 
Participants with 30% or greater reduction in disease, i.e. a RECIST Complete Response (CR) 
or Partial Response (PR) were classified as responders and those with Stable Disease (SD) or 
Progressive Disease (PD) were classified as non-responders.  
 
Tissue handling and immunohistochemistry 
Tumor samples were collected before treatment either by ultrasound-guided needle biopsy 
or a surgical procedure in the cases of lesions that were not accessible through the 
percutaneous route. Tissue was fixed in formalin and embedded into paraffin blocks. 3µm 
sections were cut from the blocks and stained with H&E (haematoxylin and eosin) and Ki-67 
(Dako Cat# M7240, Research Resource Identifier (RRID) AB_2142367). Staining was carried 
out using Leica’s Polymer Refine Detection System (DS9800) automated Bond platform. This 
platform included a primary rabbit anti-mouse IgG (<10 µg/mL) in 10% (v/v) animal serum 
plus tris-buffered saline/0.09% (ProClin™ 950) and a polymer of anti-rabbit poly-HRP-IgG 
(<25 µg/mL) in 10% (v/v) animal serum plus tris-buffered saline/0.09% (ProClin™ 950). 
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Bright-field scanning was performed on an Aperio AT2 scanner (Leica) to digitize slides for 
automated analysis. Quantification of Ki-67 staining and of the number of cells per unit area, 
as an estimate of cellularity (cells/µm2), were performed using the multiplex IHC V1.2 
module of Halo histology image analysis software (Indica labs v2.1.1637.11). Cells with Ki-67 
staining greater than an optical density of 0.31 were considered positive. The operator of 
the analytic software was blinded to MRI and treatment response results. 
 
Statistical methods 
All statistical analysis was performed in R (version 2.15.3, R Foundation for Statistical 
Computing, Vienna, Austria) and a P value of 0.05 was used as the cut-off to indicate 
significance. 
 
Intraobserver and interobserver agreement were assessed using the intraclass correlation 
coefficient (ICC). When testing for differences in means between groups, the Shapiro–Wilk 
test was used to assess for normality of data. Student’s t-test or the Mann-Whitney U test 
was then applied for evaluations on normally and non-normally distributed data 
respectively. Immunohistochemistry results were compared to diffusion parameters using 
Spearman’s correlation.  
 
3.3 Results 
Study population 
Seventeen patients were successfully recruited to this study. Mean age, 66.6 ± 9.4 (mean ± 
S.D.) and range, 43 to 81 years old. Population demographics are summarized in Table 3.2. 
After MRI imaging, 15 of the 17 participants went on to have NACT treatment with a 
combination of carboplatin and paclitaxel. The remaining 2 patients were treated with 
primary surgery and adjuvant chemotherapy. The tumours included ranged in size from 33.8 
ml to 699.9 ml and the mean tumour size was 142.9 ml. 
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Table 3.2: Population demographics of patients recruited. ECOG = Eastern Cooperative 
Oncology Group, FIGO = Fédération Internationale de Gynécologie et d'Obstétrique, ROI = 
region of interest, RECIST = Response Evaluation Criteria In Solid Tumors, CA 125 = cancer 
antigen 125, NACT = neoadjuvant chemotherapy, S.D. = standard deviation. 
Feature Value 
Number of patients 17 
Age at diagnosis, mean (range) (years) 66.6 (43 to 81) 
ECOG performance status (number of patients)  
   0-2 13 
   3-4 4 
FIGO stage (number of patients)  
   I 0 
   II 1 
   III 12 
   IV 4 
Serum CA 125 at diagnosis (IU/ml) (number of 
patients) 
 
   0-100  4 
   100-500 5 
   >500  8 
Volume of ROIs analysed (number of patients)  
   0 to 25 ml  0 
   >25 to 50 ml 3 
   >50 to 100 ml 8 
   >100 ml 6 
Treatment pathway  
   Neoadjuvant treatment 15 
   Adjuvant treatment 2 
RECIST response on CT  
   Complete response (CR) 0 
   Partial response (PR) 5 
   Stable disease (SD) 8 
   Progressive disease (PD) 2 
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Imaging 
There was a good fit of DWI images to the DKI model for the volumes of interest (VOIs) 
analyzed. Fig. 3.1 shows an example of a typical DWI image and the diffusion parameter 
maps for a 63-year old HGSOC patient who responded well to NACT. For comparison, Fig. 
3.2 displays a DWI image and the diffusion parameter maps of a 76-year old patient who 
was classified as a non-responder. The CT scans before and after therapy for both patients 
are also shown. 
 
Intraobserver and interobserver variability 
There was good intraobserver and interobserver agreement for all diffusion metrics 
measured. Results are summarized in Table 3.3. 
 
 
Diffusion metric Intraobserver ICC Interobserver ICC 
ADC 0.971 (0.967 to 0.972) 0.977 (0.975 to 0.978) 
Dapp 0.968 (0.965 to 0.971) 0.974 (0.971 to 0.976) 
Kapp 0.989 (0.986 to 0.981) 0.989 (0.986 to 0.982) 
 
Table 3.3: Intraobserver and interobserver variability for diffusion imaging metrics. ICC = 
intraclass coefficient correlation, ADC = apparent diffusion coefficient, Dapp = apparent 
diffusion, Kapp = apparent kurtosis. Values in brackets represent the 95% confidence interval. 
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Figure 3.1: Axial MRI images from a 63-year old high grade serous ovarian cancer patient 
who had a good response to neo-adjuvant chemotherapy. Images (a) to (e) were taken 
before treatment and (f) was taken after 3 cycles of chemotherapy. (a) DWI at b=1300 
s/mm2. Scale bar represents signal intensity; (b) ADC map with tumour ROI shown. Scale bar 
represents ADC x 1000 in s/mm2; (c) Dapp map. Scale bar represents Dapp x 1000; (d) Kapp 
map. Scale bar represents Kapp x 1000; Axial CT scans following intravenous contrast medium 
(e) before treatment; (f) after treatment, depicting a RECIST Partial Response (PR). 
 
53 
 
 
Figure 3.2: Axial MRI images from a 76-year old high grade serous ovarian cancer patient 
who did not respond well to neo-adjuvant chemotherapy. Images (a) to (e) were taken 
before treatment and (f) was taken after 3 cycles of chemotherapy. (a) DWI at b=1300 
s/mm2. Scale bar represents signal intensity; (b) ADC map with tumour ROI shown. Scale bar 
represents Dapp x 1000; (c) Dapp map. Scale bar represents Dapp x 1000; (d) Kapp map. Scale bar 
represents Kapp x 1000; Axial CT scans following intravenous contrast medium (e) before 
treatment; (f) after treatment, depicting RECIST Progressive Disease (PD). 
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Predicting treatment response 
Of the 15 patients to undergo NACT, there were 10 responders and 5 non-responders. A 
significant difference was found in the pre-treatment mean Kapp between the responders 
and non-responders: 0.69 ± 0.13 versus 0.51 ± 0.11 (mean ± S.D.) respectively; Mann-
Whitney U test, P = 0.02 for a difference between these two groups. Dapp was not found to 
be significantly different between responders and non-responders: 1.44 ± 0.30 versus 1.51 ± 
0.32 x 10-3 mm2/s respectively; P = 0.68 and the difference in ADC between the groups was 
similarly non-significant: 1.22 ± 0.24 x 10-3 mm2/s versus 1.30 ± 0.27 x 10-3 mm2/s 
respectively, P = 0.77. Boxplots of the median ADC, Dapp and Kapp values for the responders 
and non-responders are shown in Fig. 3.3. 
 
 
Figure 3.3:  Box plots showing median and inter-quartile ranges of diffusion parameters for 
responders and non-responders to neoadjuvant chemotherapy. (a) ADC; (b) Dapp; (c) Kapp. 
 
Correlation with cellularity and Ki-67 expression 
Localization of the Ki-67 stain in all cases was to the nucleus of cells, where the Ki-67 protein 
is expected to be found (103). Ki-67 staining was also subjectively observed to be greater in 
tissue that was confirmed as cancerous on H&E, which is consistent with the expression 
pattern of this protein that is known to be upregulated in ovarian cancer (104).  
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Figure 3.4 shows the typical appearances of the H&E and Ki-67 staining for a responder 
(Figure 3.4 a) and a non-responder (Figure 3.4 b) to therapy. An example of the automated 
segmentation of Ki-67 positive cells in Halo, is shown in Figure 3.4 c, illustrating the accuracy 
of the cell classification by the software. 
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Figure 3.4: Examples of histology from two patients with HGSOC: a responder and a non-
responder. (a) 1x magnification H&E slide of a patient who subsequently responded well to 
chemotherapy; (b) 1x magnification Ki-67 staining from the same patient (positive tissue 
shown in brown and negative tissue shown in blue); (c) 1x magnification H&E slide from a 
patient who subsequently did not respond well to chemotherapy ; (d) 1x magnification Ki-67 
staining from the same patient (positive tissue shown in brown and negative tissue shown in 
blue); (e) 20x magnification of Ki-67 staining in a HGSOC patient, with positive cells in dark 
brown and background counter staining in blue; (f) automated image segmentation in Halo 
for quantification of Ki-67 staining. Positive cells colored dark brown by software and 
negative cells colored blue by software.  
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Cellularity exhibited a positive correlation with Kapp, (Spearman rho (rs) = 0.49, P = 0.04) and 
negative correlations with both ADC (rs = -0.77, P = 0.02) and Dapp (rs = -0.73, P = 0.03). Kapp 
correlated positively with the percentage of cells expressing Ki-67 (rs = 0.53, P = 0.03), but 
ADC and Dapp did not correlate with Ki-67, P = 0.55 and P = 0.15 respectively. A scatterplot of 
mean tumor Kapp against Ki-67 quantification is shown in Figure 3.5. 
 
 
 
 
Figure 3.5: scatterplot of mean tissue Kapp against percentage of cells positive for Ki-67 
staining (optical density >31). White circles indicate responders to neo-adjuvant 
chemotherapy, black circles indicate non-responders and crosses indicate the two patients 
treated with primary surgery before starting adjuvant chemotherapy. 
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3.4 Discussion 
This study demonstrated a significant difference in the value of the DKI metric, Kapp before 
treatment in responders and non-responders to neo-adjuvant chemotherapy in HGSOC. This 
suggests that it may be possible for Kapp to predict the response to neoadjuvant 
chemotherapy in treatment naïve HGSOC patients. Tumours with a higher mean Kapp before 
the start of chemotherapy were found to respond better to treatment whereas, neither ADC 
nor Dapp could differentiate future responders from non-responders. All three diffusion 
metrics correlated with cellularity, which was an expected finding as cells form the major 
barrier to the diffusion of water in tissue (105-107). Immunohistochemistry results also 
confirmed that the previously reported relationship between Kapp and Ki-67 also apply to the 
patient cohort recruited here (95, 96). 
The magnitude of the Kapp term in DKI reflects the degree of kurtosis applied to the Gaussian 
diffusion model by the tissue structure and consequently relates to tissue heterogeneity 
(108). Heterogeneity in turn is used to help determine tumour grade on histopathology. In 
some tumours, DKI may therefore be of diagnostic value for grading. Studies have already 
demonstrated that DKI can differentiate grade II and III gliomas (97, 109) as well low grade 
and high grade prostate cancer (110, 111) and borderline from malignant epithelial ovarian 
tumours. However, in the case of ovarian cancer, Kapp has not been shown to be superior to 
conventional ADC measurements at diagnosing specific epithelial tumour subtypes (95).  
From a biological perspective, the treatment response findings presented here may be 
explained by the higher cellular density and microstructural heterogeneity that is present in 
rapidly proliferating tissue, which can be probed histologically with Ki-67 and non-invasively 
by Kapp. Rapidly dividing and heterogeneous tumours may be more sensitive to therapies 
that target cellular replication, such as carboplatin which inhibits DNA synthesis required for 
new cell development (112) and paclitaxel which disrupts the microtubule formation 
necessary for mitosis (113). In additional to this, more proliferative epithelial ovarian cancer 
subtypes like HGSOC are known to respond better to chemotherapy than low grade serous 
ovarian cancer (114). Low proliferation in epithelial ovarian cancer was also previously 
found to relate to chemoresistance (115) and a number of other high Ki-67 expressing 
cancers have been shown to be more sensitive to chemotherapy (98, 99). These past studies 
59 
 
all support the possibility of a true relationship between HGSOC proliferation measured by 
Kapp and response to NACT treatment. 
A further application of DKI, could be to investigate tumour microstructure and growth 
alongside Ki-67 and other immunohistochemistry or histological markers. Unlike Ki-67 tissue 
measurements that are taken from a small section of tumour, DKI could be used to study 
proliferation across a larger lesion or to assess multiple cancer deposits simultaneously. 
HGSOC tumours are known to be heterogeneous (116, 117) and therefore a biopsy sample 
may not be representative of the Ki-67 expression and cellularity across the entire tumour 
volume. DKI measurements from the full tumour burden may therefore provide 
complementary information to that gained from biopsy specimens alone. 
This study’s limitations include the possibility of sampling error in the tissue that was used 
to quantify Ki-67 expression and cellularity, as only small areas of tumour were represented 
on histology while the diffusion imaging parameters that these specimens were compared 
to originated from larger volumes of tissue. Other confounding factors that may have 
influenced treatment response but were not considered include the initial tumour burden of 
patients, the stage of the disease at recruitment, patient co-morbidities and genetic factors 
such as the presence of BRCA and TP53 mutations that can influence the effectiveness of 
chemotherapy (118-120). 
In conclusion, this study provide evidence of a potentially clinically-relevant relationship 
between DKI-derived diffusion metrics and the response to neo-adjuvant chemotherapy in 
HGSOC, particularly with regards to those treatments involving drugs that target cellular 
proliferation. These findings have the potential to be applied to stratify treatment in ovarian 
cancer and to rapidly escalate patients to alternative targeted or combinational therapeutic 
approaches, while reducing morbidity from the side effects of less efficacious drugs. DKI 
may also offer clinical value as an adjunct to histopathology for the measurement of ovarian 
cancer proliferation. There is now a need for larger trials to further explore the applications 
of DKI in HGSOC patients and other tumour types. A larger dataset would also enable a 
receiver operating characteristic (ROC) analysis of Kapp value and response to treatment that 
could be used to look for a cut-off of Kapp value that may predict response to NACT. 
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Chapter 4 
 
Sodium MRI in ovarian cancer 
________________________________ 
 
4.1 Background 
In a simple two compartment model of tissue, the tissue sodium concentration (TSC) is a 
weighted average of the intracellular and extracellular sodium concentrations that can be 
expressed as: 
 TSC = [NaDEF]	. EVJ + [NaDLF]	. IVJ, 
 
Where EVJ is the extracellular volume fraction, IVJ is the intracellular volume fraction, [NaDEF] is the extracellular sodium concentration and [NaDLF] is the intracellular sodium 
concentration. However, because 
 EVJ = 1 − 	IVJ 
 
and cellular density, ρc is proportional to IVJ, equation (4.1) can be rewritten as 
 TSC = [NaDEF] − 	k	. ([NaDEF] − [NaDLF])	. ρQ 
 
Where k is a scaling factor for the conversion of IVJ to cellular density. Assuming, [NaDEF] ≥[NaDLF], it can be inferred from the above expression that TSC measured by MRI would 
have approximately a negative linear relationship with ρc. 
(4.1) 
(4.2) 
(4.3) 
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In cancer treatment the aim is to reduce the cellular density of tumours by destroying 
cancerous cells. If TSC from sodium MRI (23Na-MRI) is able to measure ρc then 23Na-MRI may 
also be of clinical value for monitoring cell death after cancer treatment. 
Body imaging using sodium MRI is technically challenging. The signal from sodium MRI is 
significantly smaller than the signal in proton MRI. This is because of the lower abundance 
of sodium in the human body compared to 1H, the spin on the sodium nucleus of 3/2 
compared with 1/2 for hydrogen and the gyromagnetic ratio of sodium, 70.8×106 radT−1s−1 
(11.26 MHz/T) which is 4 times smaller than that of 1H. When all effects are considered, the 
total sodium signal available on MRI in human tissue is only about 1/22,000th the size of the 
proton signal (121). High static magnetic (B0) fields must therefore be used with sodium MRI 
to compensate for the low signal and to improve the signal to noise ratio. A further 
challenge in sodium imaging is that after radiofrequency (RF) excitation, there is a rapid bi-
exponential decay of the sodium signal that drastically limits the timeframe during which an 
image can be recorded. As a result of this, very fast filling of k-space must always be 
employed in sodium imaging.  
Because of a difference in the T1 relaxation times of free and bound sodium it is possible to 
separate the intracellular and extracellular signal on sodium MRI to create tissue sodium 
concentration (TSC) and intracellular weighted sodium (IWS) maps. Extracellular sodium is in 
free aqueous solution and has a T1 of ~47ms whereas intracellular sodium is weakly bound 
to other intracellular charges and has a much shorter T1 decay time of only ~22ms. An 
inversion recovery pulse is therefore able to suppress the longer T1 signal from extracellular 
sodium and create images that display only the more physiologically important intracellular 
sodium concentration. 
The peritoneal deposits of HGSOC are more superficially located and more accessible to 
percutaneous biopsy. For this reason, peritoneal HGSOC tissue is often sampled clinically 
and studied in research. Multi-regional sampling of tissue and repeat sampling during 
therapy however is often not practical due the invasive nature of the biopsy procedure. 
Imaging provides an alternative means to biopsy of investigating entire heterogeneous 
tumour volumes and of following cancer progress over time and sodium MRI may assist in 
the non-invasive investigation of peritoneal HGSOC. This study looks at the application of 
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23Na-MRI using 3D-cones in the imaging of peritoneal cancer deposits in HGSOC and 
explores the relationship of histologically measured tumour cellularity with the imaging. 
Results from this chapter have been published in the European Journal of Radiology Open 
(122).  
 
4.2 Methods 
Study design and patient recruitment 
This was a single centre imaging feasibility study with an exploratory element to investigate 
the biological factors responsible for the sodium MRI signal. Patients were recruited under 
the MISSION-ovary research protocol with the only alteration to the inclusion and exclusion 
criteria being that the patients were required to have superficial peritoneal deposits of 
cancer detectable on CT. 
Differences in the sodium MRI, DKI and MT patient groups which were all recruited from 
MISSION-ovary also emerged due to limitations on patient tolerance of long scan times that 
led to omission of one or more type of imaging for some patients and because of the 
requirement for specialist physics support for sodium imaging that was not always available.  
 
MRI technique 
23Na-MRI and 1H-MRI were carried out on patients using a 3T MR system (MR750 GE 
Healthcare, Waukesha WI). The 23Na-MRI was performed with a custom made single-
channel transmit/receive surface coil using a 3D-cones readout (123) which has been shown 
to provide better contrast and more reproducible results than other k-space sampling 
trajectories such as cylindrical stack-of-stars (SOS) and 3D-spokes kooshball (124). An 
adiabatic pulse was used for inversion in IWS imaging and an isotropic resolution of 5.6 mm 
was prescribed for both TSC and IWS imaging. Sodium calibration phantoms were included 
in the imaging field of view (FoV) for use in generating sodium concentration maps. The 
repeatability of this imaging method was demonstrated in an earlier study performed by a 
group at the University of Cambridge Department of Radiology and Manchester University 
(125). Phantoms consisted of 50 mL tubes of diameter 6 cm containing sodium chloride 
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(NaCl) with 4% agar at two sodium concentrations: 20 mM and 80 mM. T2-weighted 1H-MRI 
was performed with a fast spin echo pulse sequence and a 32-channel cardiac array. Patients 
were not moved or repositioned during the coil change. The radiofrequency (RF) power used 
for the 23Na-MRI was adjusted for each patient to achieve penetration up to a maximum 
depth of 12 cm which was sufficient to image the peritoneal lesions in all cases. Detailed 
scan parameters for sodium and proton imaging are given in Table 4.1. 
 
 
Imaging parameter 23Na-MRI TSC and B1 mapping 23Na-MRI IWS  1H T2-weighted 
   TR 100 ms 250 ms 4000 ms 
   TE 0.5 ms 0.5 ms 91.1 ms 
   TI n/a 30 ms n/a 
   Flip angle  90° for TSC, 
30° and 60° for B1 mapping 
90° 90° 
   Slice thickness 5.6 mm 5.6 mm 6 mm 
   In plane resolution 5.6 mm x 5.6 mm 5.6 mm x 5.6 mm 1.33 mm x 1.33 mm 
   FoV 30 cm 30cm 34.0 cm x 29.9 cm 
   Matrix 50 x 50 (reconstructed to 120 x 
120) 
50 x 50 (reconstructed 
to 120 x 120) 
256 x 256 
   NEX 6 6 8 
   ETL n/a n/a 16 
   Total scan time 1 min 58 sec  4 min 56 sec 1 min 54 sec 
   Pulse sequence GE with 3D-Cones readout IR- GE with 3D-Cones 
readout 
Single shot fast spin 
echo (SSFSE) 
 
Table 4.1: Imaging parameters for TSC (total sodium concentration), IWS (intracellular 
weighted sodium) and T2-weighted imaging. TR = repetition time, TE = echo time, TI = 
inversion time, FoV = field of view, NEX = number of excitations, ETL = echo train length, GE = 
gradient echo. 
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Post processing 
Processing of sodium images was carried out with in-house software written in MATLAB 
(The MathWorks Inc., Natick, MA, 2000). The method described by Miller (1993) was used 
to remove noise from the images (126). This correction is suitable for use in low SNR images. 
Briefly, the correction involves squaring the image, selecting an ROI in a background region 
with noise only and no true signal, measuring the mean pixel value in this background 
region and subtracting this value from all pixels in the squared image. 
 
Radiofrequency field inhomogeneity correction  
 
Because of a loss of signal intensity due to reduced RF penetration deep into tissues a B1 
artefact (transmit and receive) correction had to be performed on images. A B1 map was 
created using the dual angle method for gradient echo (127, 128) with images collected at 
flip angles of 30° and 60°. Using this method for 2 images formed with nominative flip angles 
αnom and 2αnom  the ratio, rI, of the image intensities was,  
 rI	 = 	sin(αTUV)	/	sin	(2αTUV) 	= 	1	/	2cos	(αTUV)  
 
 
which gave a relative flip-angle (or equivalently B1 field) correction factor (rB1) of, 
 
 rB1	 = [	cosXY	(	1	/	2rI	)]	/αTUV 
 
 
True flip angles (αtrue) were then calculated by multiplying the nominative flip-angle by the 
rB1 value calculated at each pixel. 
After calculating the true flip angle maps for the images, a signal correction formula was 
derived as follows to compensate for the non-uniformities of both the transmit and the 
receive fields. 
For the transmit B1 the gradient echo signal,	S, was given by the formula, 
 S	 ∝ 	[Na] 	sin(α[\]^)	 _1 − eX`a `Yb c 	(1 − (cos	(α[\]^))eX`a `Yb ) 
(4.5) 
(4.6) 
(4.4) 
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This equation can be simplified because for the sodium pulse sequence used in this study TR 
>> T1, causing eX`a `Yb  to approach zero, resulting in the approximation of, 
 
 S ∝ [Na]. sin	(α[\]^)	 
 
When compensating for the receive-only B1 for a surface coil, the signal, S is also directly 
proportional to the receive B1 so that, S ∝ α[\]^  
The overall relationship of the combined receive and transmit signal to the flip angle could 
therefore be reduced to:  S	 ∝ 	[Na]. α[\]^	. sin(α[\]^) 
 
or, 
 [Na] ∝ S [αdefg	. sin(αdefg)]⁄  
 
Signal from the B1 maps was masked to exclude from the image analysis areas with very low 
flip angle and areas with flip angles that would create unwanted inversion. This was because 
in such regions the signal was considered too small in comparison to image noise to give 
reliable quantitative information on sodium concentration. Areas with flip angle 5% greater 
than or less than 180° and 360° were removed. 
Sodium maps (TSC and IWS) were calculated from a calibration curve created with 
phantoms included in the field of view of the patient scans. ROIs were selected from inside 
the tubes and used to derive the linear relationship between Na+ concentration and MR 
signal based on the method described by Christensen JD et al (129). This involved solving 
simultaneous equations of the form (4.11) and (4.12) for a and b where C1 and C2 were the 
known sodium concentrations of the calibration phantoms and S1 and S2 were the 
corresponding imaging signal intensities for these phantoms. Leading to a linear calibration 
equation of the form shown in (4.13).  
 
(4.10) 
(4.8) 
 
(4.7) 
(4.9) 
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 𝐶Y = 𝑎𝑆Y + 𝑏 	𝐶m = 𝑎𝑆m + 𝑏 
 𝐶 = 𝑎 + 𝑏𝑆 
 
where, 𝑎 = 	 noXnpqoXqp and 𝑏 = 	 npqoXqpqoXqp  
 
ROIs were drawn on the T2-weighted images by a single observer using OsiriX (version 3.8.1, 
Pixmeo, Geneva, Switzerland) around all slices encompassing complete peritoneal deposits 
and around the adjacent areas of right gluteal muscle as a normal reference tissue for 
comparison with the tumour. Only solid areas of cancer on the T2-weighted images were 
included. ROIs were restricted to superficial areas where the signal was not masked and 
care was taken to avoid areas with artefact. The ROIs were reviewed by a radiologist with 
eight years of experience as an attending physician and co-registered with the sodium maps 
to which the ROIs were imported for analysis. For patients with multiple peritoneal deposits, 
ROIs were combined into a single tumour volume.  
Tissue samples were collected from the peritoneal deposits of patients 1-14 days (median 7 
days) after imaging either by ultrasound guided biopsy or at surgery. Samples were fixed in 
paraffin blocks for storage and cut into 3 µm sections that were retrieved with sodium 
citrate. Sections were stained with haematoxylin and a cell count and tissue area 
quantification were performed on the sections using automated histology image analysis 
software (Halo, v2.1.1637.11, Indica labs). Cellularity (cell density), ρQ was estimated from 
the cell count (N) and tissue area (A) in µm2 as follows: 
 ρQ = N / A * 1000 
(4.13) 
(4.12) 
(4.11) 
(4.14) 
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Statistics 
All statistical analysis was performed in R (v2.15.3, R Foundation for Statistical Computing, 
Vienna, Austria). For comparison of means, the Shapiro-Wilk test was used to assess data for 
normality and the Student’s t-test or Wilcoxon test was then applied to evaluate 
significance. Cellularity was compared to sodium concentrations from MRI (TSC and IWS) 
using Spearman’s correlation. 
 
4.3 Results 
Patients 
Twelve high grade serous ovarian cancer patients were recruited: median age 69 (range 52-
81) years. The majority of patients (10/12) had FIGO (Fédération Internationale de 
Gynécologie et d'Obstétrique) stage III or IV disease. Table 4.2 gives detailed sample 
population characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Population demographics of patients recruited. ECOG = Eastern Cooperative 
Oncology Group, FIGO = Fédération Internationale de Gynécologie et d'Obstétrique, CA 125 
= cancer antigen 125. 
 
Imaging 
Signal-to-noise ratios of 82.2 ± 15.3 and 15.1 ± 7.1 were achieved for tumour TSC and IWS 
imaging respectively. The total sodium imaging time for each patient was under 11 minutes 
(TSC imaging = 1 min 58 sec, IWS imaging = 4 mins 56 sec, images for dual flip angle mapping 
= 3 min 56 sec). When the time for positioning and localisation with proton imaging is added 
the average time for a sodium imaging session increases to around 20 minutes. High signal 
intensity artefacts appeared at the edges of images after RF field inhomogeneity corrections 
because of small mismatches in alignment between B1 maps and sodium signal images at 
the interfaces of high sodium signal changes such as between air and tissue. These 
Feature Value 
Number of patients 12 
Age, median (range, years) 69 (52-81) 
ECOG performance status (number of patients)  
   0-2 9 
   3-4 3 
FIGO stage (number of patients)  
   I 0 
   II 2 
   III 8 
   IV 2 
Serum CA 125 (IU/ml, number of patients)  
   0-100  4 
   100-500 3 
   >500  5 
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mismatches were primarily due to patient movement and were found exclusively at imaging 
borders and therefore were not present on ROIs derived from peritoneal deposits or muscle. 
Examples of the 23Na-MRI images and changes with post-processing are shown in Figure 4.1. 
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Figure 4.1: 73-year old high grade serous ovarian cancer patient. P1 and P2 represent slices 
through the two sodium phantoms. The green outline shows a peritoneal cancer deposit. (A) 
T2-weighted image. (B) Sodium B1 map, scale bar represents arbitrary units. (C) Total sodium 
image; scale bar represents image intensity. (D) Intracellular weighted sodium image; scale 
bar represents image intensity. (E) Masked total sodium concentration map; scale bar 
represents sodium concentration in mM. (F) Masked intracellular weighted sodium 
concentration map, scale bar represents sodium concentration in mM. (G) Fused T2W image 
and total sodium concentration map. (H) Fused T2W image and intracellular weighted sodium 
concentration map.  
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Sodium quantification and tumour cellularity 
The mean tumour volume analysed from the regions where the sodium maps were 
successfully constructed was 45 ± 24 mL. The TSC concentrations for peritoneal cancer 
deposits and gluteal skeletal muscle were 56.8 ± 19.1 mM and 33.2 ± 16.3 mM respectively 
(mean ± standard deviation); Wilcoxon signed-rank test for difference between groups, P < 
0.001. IWS values for peritoneal cancer and muscle were 30.8 ± 9.2 mM and 20.5 ± 9.9 mM 
respectively; Wilcoxon signed-rank test for a difference between these two groups, P = 0.01. 
These results are summarised in the boxplots shown in Figure 4.2.  
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Figure 4.2: Box plots showing TSC (total sodium concentration) and IWS (intracellular 
weighted sodium) values for cancer and muscle. 
 
An example of the typical histological appearances for a 73-year old HGSOC patient are 
shown in Fig. 4.3 together with the automated cell counting segmentation. Scatterplots of 
tumour cellularity (ρQ) compared with sodium concentrations as measured on imaging are 
shown in Fig. 4.3 (C) and 4.3 (D). TSC displayed a strong negative correlation with cellularity, 
Spearman’s rho = -0.92 and P < 0.001. There was no significant Spearman correlation found 
between IWS concentration and cellularity, P = 0.44. 
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Figure 4.3: Tumour tissue from a 73-year old high grade serous ovarian cancer patient; (A) 1x 
magnification haematoxylin stained slide of tumour tissue; (B) automated cell segmentation 
used for cell counting. Scatterplots of; (C) tissue sodium concentration against cellularity, (D) 
intracellular weighted sodium concentration against cellularity. 
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4.4 Discussion 
This study demonstrated the feasibility of using 23Na-MRI to image peritoneal lesions in high 
grade serous ovarian cancer patients for the first time. The completion of sodium imaging in 
approximately eleven minutes was enabled using a 3D-cones readout, a surface 
transmit/receive coil and a post-processing analysis method to correct for RF field non-
uniformity. Short acquisition times are important for the clinical translation of 23Na-MRI and 
these results represent a moderate improvement to previously reported scan times in the 
abdomen. The comparison of tumour sodium quantification to histology preformed here 
also provided validation that TSC measured by 23Na-MRI is an effective biomarker of tumour 
cellularity. 
Sodium MRI has been used in the past to demonstrate the higher sodium concentration of 
cancers compared to healthy tissue. One study demonstrated a 63% higher TSC in malignant 
breast lesions compared to glandular tissue (130). Other studies in glioma have found 
increases in both the IWS and TSC of glioma compared to normal appearing white matter 
(NAWM) (131). These results are in agreement with the higher sodium concentrations found 
here for ovarian cancer compared to healthy tissue. The higher standard deviation of TSC 
also agrees with previous evidence that IWS is more tightly regulated than TSC and the fact 
that HGSOC is known to be heterogeneous in nature. 
Cellularity has already been shown to relate to the outcome of cytoreduction in HGSOC 
(132) and to be predictive of the response of breast cancer to neoadjuvant chemotherapy 
(133). In breast cancer cellularity is also used more directly in the Miller-Payne method for 
the histological assessment of treatment response (134). For HGSOC treatment, the first line 
chemotherapy regimen of a combination of a platinum-based drug and a taxane has not 
changed for the past 30 years despite poor patient outcomes (116). There is now ongoing 
research to develop more targeted HGSOC therapies like PARP (poly ADP-ribose polymerase 
) inhibitors (135), VEGF (vascular endothelial growth factor) inhibitors (136) and immune 
checkpoint inhibitors (137) in an attempt to improve the outlook for the disease. 
With the emergence of new therapies in heterogeneous cancers like HGSOC, there is an 
associated need for imaging to provide greater detail on tumour structure and function so 
that patients can be better stratified to the optimal treatment option for their particular 
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subtype of disease. The availability of alternative therapies also provides the opportunity for 
non-responsive patients to switch to more effective drugs and increases the urgency for the 
development of reliable early response detection methods. The measurement of cellularity 
with 23Na-MRI demonstrated here provides information on tumour composition and can 
potentially be employed to monitor the evolution of tumour cellular content over time and 
following treatment. This could have implications for patient management in HGSOC and 
other malignancies where the detection of cell death and the monitoring of cellularity 
changes are of clinical relevance. Unlike other imaging methods like diffusion MRI that may 
also measure cellularity, 23Na-MRI has the advantage that it is unlikely to be as affected by 
the presence of physical structures like membranes or fibrous tissues that alter diffusion. 
Despite the strong significance of the relationship between TSC and cellularity found here, 
no correlation between cellularity and IWS could be detected. IWS concentration in cancer 
is influenced by a large number of biological processes that may have a greater effect on the 
IWS concentration than cellularity. For example, the IWS 23Na-MRI signal may be affected by 
the energy status of tumours due to the ATP and oxygen requirements of the sodium pump 
(138, 139). In cancer there is mitochondrial dysfunction (140) as well as metabolic 
reprogramming that shifts glucose away from the production of ATP by oxidative 
phosphorylation and towards the manufacture of new nucleotides, lipids and amino acids 
needed for cell replication and unregulated tumour growth (141, 142). Voltage gated 
sodium channel expression is also upregulated in many cancers (143-145) and although the 
purpose of these channels in cancer is not yet clear they may represent a further 
mechanism by which the intracellular sodium concentration is altered in malignancy. 
Furthermore, aggressive tumours such as HGSOC have higher Na+/H+ antiporter activity 
which allows sodium to enter the cell in exchange for a H+ efflux, that is used to create an 
acidic extracellular environment to stimulate enzymes that breakdown of surrounding 
extracellular matrix structures and facilitate cancer invasion (146). TSC signal in comparison 
to IWS is more dominated by the high concentration of sodium in the extracellular space 
and is less affected by the movement of sodium in and out of cells. This is because TSC is a 
measure of total tissue sodium that includes both the intracellular and extracellular 
environments.  
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The findings of this study are limited by the possibility of errors introduced by patient 
movement during the sodium/proton coil change and the creation of edge artefacts in post-
processing. The optimisation of RF power to image superficial peritoneal lesions also meant 
that gluteal sodium measurements could not include some deeper muscle regions. 
Reasonable measures were taken to minimise the effects of these limitations however 
through the exclusion via masking of possible inaccurate sodium map areas and the 
application of an RF inhomogeneity correction. 
In conclusion, rapid 23Na-MRI using 3D-cones was successfully performed in a technically 
challenging area of the body. This study shows for the first time that 23Na-MRI can assess 
peritoneal deposits in HGSOC patients and that TSC measured by 23Na-MRI correlates 
strongly with tumour cellularity. The non-invasive quantification of sodium using MRI has 
the potential to provide information on cell viability, sodium transporters, metabolic 
activity, cell membrane integrity and tumour response to therapy. The rapid scanning 
method shown here demonstrates that larger human studies to evaluate 23Na-MRI in the 
abdomen are feasible. Further work is now needed to investigate other clinical applications 
of sodium MRI and to explore the utility of TSC in monitoring cellularity changes in response 
to cancer treatment. 
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Chapter 5 
 
The repeatability of magnetization transfer 
imaging in the female pelvis 
________________________________ 
 
5.1 Background 
Before addressing the use of MT imaging in ovarian cancer a study on the repeatability of 
the technique was performed in the healthy female pelvis. The aim of this work was to 
determine whether the pelvic imaging was sufficiently repeatable and could subsequently 
be applied to the study of ovarian cancer. This data was collected at the University of 
Cambridge Department of Radiology prior to the start of this PhD but was analysed by me 
during the PhD. 
Magnetization transfer ratio (MTR) is defined as the percentage change in signal with the 
“off –resonance” pulse off and on. Mean MTR values have been reported for MT performed 
on a diverse set of body structures and tissues in health and disease. Work on the post-
mortem brains of multiple sclerosis (MS) patients found mean MTRs of 30.0% ± 2.9 in 
remyelinated white matter lesions and 23.8% ± 4.3 in demyelinated lesions (147). Other 
brain studies generated MTR 30.77% ± 0.29; P = 0.037 for grey matter in patients with mild 
cognitive impairment and 29.37% ± 0.41; P = 0.000) in those with Alzheimer’s dementia 
(148). A study on whole body MT imaging produced MTR results for white matter of 51.1% ± 
1.0, for gray matter of 42.2% ± 1.3, for skeletal muscle 50.3% ± 2.1, liver 39.4% ± 3.2, spleen 
31.8% ± 2.6, renal cortex 30.4% ± 1.9 and renal medulla 25.6% ± 1.3 (149). In another 
published study, MTR was 34.4%-54.9% for muscle, 10.3%-12.6% for subcutaneous fat and 
22.8% - 46.9% (P < 0.001) for liver at frequency offsets greater than 400Hz (150). Similar 
research on prostate generated MTRs in the range of 6.18% ± 1.63 for healthy controls 
(151). Imaging of fibrotic bowel wall using two different mouse models of Crohn’s disease, 
produced mean normalized MTRs of 0.45 ± 0.05 and 0.58 ± 0.08 (P = 0.0003) for the two 
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models using a 10 kHz off-resonance pulse and mean normalized MTRs of 0.53 ± 0.08 and 
0.64 ± 0.07 (P = 0.003) for the two models using a 5 kHz off-resonance pulse (152). Previous 
pelvic MT work produced MTR values of (23.8% ± 6.7, P < .01) for normal cervical stroma 
and (24.3% ± 3.6, P < .01 ) for normal endometrium (153). 
There are very few repeatability studies involving MT. One such study undertaken in the 
brain explored areas of white matter and resulted in an MTR value averaged over time for 
five participants of 30.1% but did not use coefficient of variation (COV) to estimate 
repeatability. Instead this study used the test/retest reliability coefficient although it did 
recommend COV calculations as an alternative method of performing a repeatability 
analysis (154). This chapter presents an example of the measurement of MTR in major pelvic 
tissues and their repeatability. MTR results of repeatability experiments from the female 
pelvis have never previously been published. 
 
5.2 Methods 
Six healthy female volunteers aged 23 to 54 were recruited for pelvic imaging. They were 
scanned at 1.5T on two separate sessions approximately one week apart. Imaging was 
performed with body coil excitation and a 12-channel receiver array (Discovery MR450, GE 
Healthcare, Waukesha WI). For premenopausal women, both sets of scans were completed 
between days 6 and 14 of the menstrual cycle. MT images were acquired via a 3D fast 
spoiled gradient echo (FSPGR) sequence (TR 15 ms, TE 1.1 ms, FOV 38 cm, matrix 192x192, 
32 or 64 slices, thickness 5 mm) applied with and without an additional 8ms Fermi pulse 
(offset 2200Hz, nominal flip angle 360°). Fractional MTR maps were calculated as;  
 
(MToff – MTon) / MToff x 100 
 
ROIs were drawn directly onto MTR maps to sample signal from different tissue types. 
Matched regions of interest (ROIs) from the two examinations that each volunteer 
underwent were selected and analyzed with ImageJ (155). The mean pixel intensity and 
standard deviation for the ROIs was calculated from the ImageJ measurements.  
(5.1) 
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The mean MTR across all participants was found for selected pelvic tissue types. MTR values 
were reported with and without normalization to gluteal muscle. Normalization was 
performed by dividing the mean ROI MTR by the mean gluteal muscle MTR of individual 
images. This normalization would be expected to be necessary if there were variations in 
MTR due to hardware performance or other inter-subject factors. The change in MTR with 
repeat imaging for each tissue type was assessed via the test-retest coefficient of variation 
(COV). The COV was found by dividing the standard deviation, σi for each pair of MTR values 
by its mean, µi according to equation (5.2) below (156) . 
 𝜎s𝜇s  
 
The root mean square coefficient of variation (RMS COV) for each tissue type from the 
volunteers was then calculated as: 
 
RMS	COV = 	wx _𝜎s𝜇scmsyTsyY𝑛  
 
where n is the number of tissue sample pairs identified. 
RMS COV represents an estimate of the variability in signal between repeat images. Not all 
tissue types explored in this study were identifiable in every volunteer. Only samples where 
the tissue could be convincingly identified were included. Samples were also removed from 
the analysis if the co-registration between scans could not be accurately performed. As a 
result, the sample sizes for the pelvic tissues analysed in this study varies slightly. 
 
        COV = (5.2) 
(5.3) 
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No formal hypothesis testing was performed in this repeatability study but a RMS COV of 
less than 20% was taken as an indicator of good repeatability.  
 
5.3 Results 
Tissue MTR values 
It was possible to identify nine different tissue types in the images we collected. Mean first 
visit MTR values from fat and bone were low with a value of 2.39 ± 0.91 for subcutaneous 
fat and 3.35 ± 1.16 for bone from the femoral head. Conversely, the gluteus maximus 
muscle displayed a first visit MTR almost twenty times greater than fat at 41.85 ± 3.87. 
Myometrial MTR was slightly lower than skeletal muscle MTR at 32.66 ± 3.94.  
Figure 5.1 shows the repeat MT images and region of interest (ROI) selections from the 
femoral heads 5.1 a and b and the gluteal muscle 5.1 c and d for a pair of scans from one 
participant.  
The mean MTR values before and after normalization for each tissue type are shown in 
Table 5.1 and Table 5.2 respectively. The magnitude of the percentage change in normalized 
and non-normalized MTRs with repetition are also given. 
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Figure 5.1: ROI from the left femoral heads on (a) test and (b) re-test scans: images are from 
the same patient and were analyzed using ImageJ. (c) Test and (d) re-test ROI selection for 
gluteal muscle. 
 
 
 
 
a 
d c 
b 
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Coefficients of variation (COV) 
Coefficients of variation for different tissue types ranged from 3.7% for muscle to 49.0% in 
bone before normalization. Myometrial MTR showed good repeatability (RMS COV 6.8%), 
Normalized and non-normalized RMS COV values for all the tested tissues are displayed in 
Table 5.1 and Table 5.2 respectively and graphically in Figure 5.2.  
 
 
Tissue type Visit 1 MTR  
(Mean ± SD) 
Visit 2 MTR 
(Mean ± SD) 
Mag. of % change in MTR 
(Mean ± SD) 
RMS COV 
(%) 
Subcutaneous fat (n=5) 2.39 ± 0.91 2.15 ± 0.54 23.6 ± 7.1 17.7 
Right femoral head (n=4) 3.35 ± 1.16 2.51 ± 1.05 45.8 ± 31.1 49.0 
Bladder contents (n=4) 4.03 ± 1.80 3.27 ± 1.48 18.9 ± 10.4 17.0 
Vertebral body (n=4) 13.09 ± 6.82 13.37 ± 7.39 31.8 ± 26.5 22.3 
Bowel (n=5) 20.09 ± 3.14 18.96 ± 2.68 16.8 ± 14.3 15.2 
Myometrium (n=4) 32.66 ± 3.94 33.06 ± 3.17 8.9 ± 4.7 6.8 
Intervertebral disc (n=4) 37.33 ± 3.34 38.40 ± 2.03 8.3 ± 1.6 5.9 
Psoas (n=5) 41.42 ± 4.47 42.33 ± 1.80 9.9 ± 9.8 8.6 
Gluteus maximus (n=5) 41.85 ± 3.87 42.46 ± 2.43 4.6 ± 2.9 3.7 
 
Table 5.1: Table of non-normalized mean percentage MTR and RMS COV values for the 
selected pelvic tissues. 
 
Tissue type Visit 1 MTR  
(Mean ± SD) 
Visit 2 MTR 
(Mean ± SD) 
Mag. of % change in MTR 
(Mean ± SD) 
RMS 
COV (%) 
Subcutaneous fat (n=5) 0.06 ± 0.03 0.05 ± 0.01 23.0 ± 9.5 18.6 
Right femoral head (n=4) 0.08 ± 0.03 0.06 ± 0.02 43.5 ± 32.9 49.5 
Bladder contents (n=4) 0.09 ± 0.04 0.08 ± 0.03 20.3 ± 8.6 17.4 
Vertebral body (n=4) 0.31 ± 0.16 0.30 ± 0.16 35.5 ± 32.6 24.7 
Bowel (n=5) 0.49 ± 0.10 0.45 ± 0.05 19.3 ± 11.5 16.3 
Myometrium (n=4) 0.78 ± 0.02 0.78 ± 0.03 5.3 ± 0.8 3.8 
Intervertebral disc (n=4) 0.86 ± 0.04 0.89 ± 0.02 4.6 ± 1.3 3.3 
Psoas (n=5) 1.00 ± 0.13 1.00 ± 0.04 8.0 ± 9.1 7.4 
Gluteus maximus (n=5) 1.00 ± 0.00 1.00 ± 0.00 0.0 ± 0.0 0.0 
 
Table 5.2: Table of mean MTR and RMS COV values for the selected pelvic tissues 
normalized to gluteal muscle 
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Figure 5.2: COV and normalized COV for the selected pelvic tissues. 
 
 
5.4 Discussion 
In this study, pelvic MT ratios were similar to those previously reported and imaging maps 
were highly reproducible for most structures in the female pelvis. Repeatability improved 
only slightly by normalization to gluteal muscle, indicating good hardware performance 
between imaging sessions. It should be noted however that normalization as performed 
here has the disadvantage of decreasing the RMS COV for tissues with similar MTR to the 
tissue used as the standard for normalization (in this case skeletal muscle) as the tissue used 
as the standard is assigned a base value of 1.00 for each case leading to no variability in the 
normalized gluteal muscle measurements between samples. For the non-normalized data, 
myometrium and gluteal muscle showed the greatest levels of consistency between repeat 
images with RMS COV values of 6.8% and 3.7% respectively. Most other soft tissue types 
such as subcutaneous fat and fluid displayed RMS COV <20% which is generally considered 
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to indicate good repeatability for MRI although there is no definite consensus among 
researcher on his value. At the other end of the spectrum, femoral head and vertebral body 
had the highest RMS COV values at 49.0% and 22.3%. The MT maps of tissues like muscle 
and fat had superior repeatability compared to the imaging of cartilage or bone. This may 
have been influenced by the lower signal in tissues like cartilage and bone being affected to 
a greater relative degree by constant components of image noise than tissues like muscle 
with higher signal. The higher consistency measured by RMS COV suggested that MT 
imaging of the pelvis would be more reliable when used to investigate soft tissue pathology. 
This would suggest that MT may best be applied to studying lesions within soft tissue organs 
in the female pelvis and would therefore be viable for ovarian cancer imaging. 
Some tissues like fat demonstrated low RMS COV but had low MTR values suggesting that 
fat demonstrates low MT signal despite good repeatability. Clinical usefulness of the MT 
imaging of such tissues may however be limited by signal. Another limitation of this study 
was the difficulty in reliably identifying some anatomy on the MT maps that resulted in 
some tissues being analysed with fewer than six samples. 
This work provides evidence of the consistency that can be achieved from MTR maps in 
pelvic tissues. Pelvic MT is not yet widely used clinically despite the success of MT in 
neuroimaging. The demonstration of good repeatability is an important criterion in judging 
the potential for application of an imaging method to the clinical setting. Based on the 
results here, MT was subsequently applied at Cambridge to the imaging of macromolecules 
within ovarian cancer as part of MISSION-ovary and findings from this are presented in the 
next chapter.  
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Chapter 6 
 
Magnetization transfer imaging of tumour 
macromolecules in ovarian cancer 
________________________________ 
 
6.1 Background 
Collagen is the most abundant protein in the human body and the major structural 
component of the extracellular matrix (ECM). Bound water plays an important part in 
maintaining the triple helix conformation of collagen and the association of collagen into 
assemblies of sheets or fibres (157). In vitro and animal experiments have demonstrated 
that the denaturation of collagen can be detected with MT imaging (158, 159). Changes in 
ECM collagen cross-linking are known to occur in most cancers (160, 161) and in some areas 
of tumour, the collagen microenvironment is destroyed and rebuilt in a remodelling process 
to support the changing structural requirements of the tumour (162, 163). Enzymes like 
metalloproteinases that are overexpressed in cancer degrade collagen while increased 
activity of immune cells like fibroblasts simultaneously lay down new collagen fibres to 
support tissue growth and provide attachment sites for tumour cells (164). In epithelial 
ovarian cancer, remodelling of the ECM is known to occur (165) and in high grade serous 
ovarian cancer (HGSOC) a collagen-remodelling gene signature has been shown to be 
associated with poor outcome (166). Both increases and decreases in overall collagen 
deposition are associated with malignancy (167) and the measurement of total collagen in 
cancer is consequently difficult to interpret clinically.  
The basement membrane (BM) is a component of the ECM that is comprised of a specific 
type of collagen, type IV collagen or collagen IV. Unlike other parts of the ECM which are 
remodelled in cancer progression, the BM must be degraded for cancer to spread (168-171). 
Collagen IV and the protein laminin are major components of the basal lamina layer of the 
BM. The basal lamina helps to maintain cell polarity, tissue structure and restrict cell 
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movement (172). Cytoskeletal binding to the basal lamina must be lost in the epithelial-
mesenchymal transition (EMT) process through which cancer cells lose their polarity and 
cell-to-cell adhesion properties and become invasive (173). Collagen IV and laminin 
expression have both been shown to be of prognostic significance in cancers such as 
colorectal adenocarcinoma (174) and oral mucosa squamous cell carcinoma (175), where 
decreased collagen IV and laminin were associated with disease progression. 
Tumours that are growing and proliferative produce larger quantities of macromolecular 
proteins and lipids and are likely to have higher MTRs. MTR could therefore be able to 
provide information on increases in cell density and tumour expansion and invasion through 
the BM. In this study the ability of MT imaging to measure tumour cell density and the loss 
of collagen IV and laminin from the BM is assessed using a cohort of patients with HGSOC. 
 
6.2 Methods 
Patient recruitment 
Patients were recruited under the protocol of the MISSION-ovary study to undergo MT 
imaging. The inclusion and exclusion criteria for these patients was therefore the same as 
previously mentioned for MISSION-ovary and detailed in Section 1.3 of Chapter 1 of this 
thesis.   
 
Imaging and region of interest analysis 
MR imaging was performed on a 3T Discovery MR750 (GE Healthcare, Waukesha WI), with a 
frequency offset of 2200 Hz for MT imaging. 20 mg of intravenous hyoscine butylbromide 
was given to participants 10 minutes before scanning to reduce bowel motion. Detailed scan 
parameters are provided in Table 6.1. Magnetization transfer ratio (MTR) was calculated 
from MToff and MTon images (Equation (5.1)). 
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Table of imaging parameters 
 
 
Table 6.1: Scan parameters for T2 weighted, MToff (magnetization transfer off) and MTon 
(magnetization transfer on) imaging. TR = repetition time, TE = echo time, TI = inversion time, 
FoV = field of view, NEX = number of excitations. 
 
 
Regions of interest (ROIs) were drawn on T2-weighted images in OsiriX (version 3.8.1, 
Pixmeo, Geneva, Switzerland) around all ovarian cancer volumes. ROIs were reviewed by a 
radiologist, with 8 years of experience as a consultant in oncological radiology and who was 
kept blind to image analysis and subsequent tissue immunohistochemistry results. ROIs 
were imported from the T2-weighted images onto MTR maps that were co-registered in 
Osirix and mean MTRs were calculated for the cancer volumes. For patients with multiple 
tumour deposits, ROIs were combined to produce one mean tumour MTR value for each 
patient. 
 
Tissue analysis 
Tumor tissue samples were collected from patients 1 to 10 days after imaging (median 7 
days). Tissue was fixed in formalin and embedded into paraffin blocks. 3 µm sections were 
cut from the blocks and slides were stained using Leica’s Polymer Refine Detection System 
Imaging parameter T2 weighted MToff MTon 
   TR 4000 ms 24ms 24ms 
   TE 91.1 ms 2.8ms 2.8ms 
   Flip angle  90° 5° 5° 
   Slice thickness 6mm 5mm 5mm 
   FoV 34.0 cm x 29.9 cm 34.0 cm x 34.0 cm 34.0 cm x 34.0 cm 
   Matrix 256 x 256 256 x 192 256 x 192 
   NEX 8 1 1 
   Total scan time 1 min 54 sec 2 min 23 sec 2 min 23 sec 
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(DS9800) automated Bond platform with haematoxylin, collagen IV antibody (Dako, M0785. 
Dilution 1:50. Retrieval Proteinase K, 20’) and laminin antibody (Sigma, L9393. Dilution 
1:1000. Retrieval Sodium Citrate, 5’ and Proteinase K, 5’). Bright-field scanning with an 
Aperio AT2 scanner (Leica) was carried out to digitize slides and a cell count and an area 
quantification of collagen IV and laminin staining were performed on the digital slides using 
the multiplex IHC V1.2 module of Halo histology image analysis software (Indica labs 
v2.1.1637.11). For both collagen IV and laminin, tissue areas with a staining optical density 
(OD) greater than 0.355 were considered positive. The operator of the analytic software was 
blinded to MTR imaging results. 
 
Statistics 
All statistical analysis was performed in R (version 2.15.3, R Foundation for Statistical 
Computing, Vienna, Austria) and a P value of 0.05 was used as the cut-off to indicate 
significance. Immunohistochemistry quantification results were compared to the imaging 
using Pearson’s product-moment correlation. 
 
6.3 Results 
Seventeen HGSOC patients were recruited. Median participant age was 69 years, range 43 to 
81 years. Patient characteristics are summarized in Table 6.2. An example of the typical MT 
imaging appearances from a 63-year old patient is shown in Figure 6.1. The MTR for the 
HGSOC lesions of participants was 24.6 ± 3.9% (mean ± S.D.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
Table of population characteristics 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2: Population demographics of patients recruited. ECOG = Eastern Cooperative 
Oncology Group, FIGO = Fédération Internationale de Gynécologie et d'Obstétrique, CA 125 
= cancer antigen 125. 
 
 
Feature Value 
Number of patients 17 
Age, median (range) / years 69 (43 to 81) 
ECOG performance status (number of patients)  
   0-2 13 
   3-4 4 
FIGO stage (number of patients)  
   I 0 
   II 1 
   III 12 
   IV 4 
Serum CA 125 (IU/ml) (number of patients)  
   0-100  4 
   100-500 5 
   >500  8 
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Figure 6.1: Example of typical images from a 63 year old HGSOC participant. Tumour is 
outlined in red. (A) MToff; (B) MTon; (C) MTR map, scale bar represents MTR in percent; (D) 
T2- weighted image. 
 
Examples of haematoxylin, collagen IV and laminin staining for a patient are shown in Fig. 
6.2 (a), (b) and (c) respectively. Localization of collagen IV and laminin was primarily in the 
extracellular space where both of these proteins are expected to be found and haematoxylin 
localization was to the cytoplasm. Figure 6.2 (d), (e) and (f) show the segmentation of tissue 
immunohistochemistry slides for quantification by Halo, demonstrating the accuracy of the 
segmentation algorithm at detecting positive staining. For the HGSOC tissue samples, 
cellular density, defined as number of cells per unit slide area was 65.6 ± 28.8 (mean ± S.D.) 
x 103 cells/mm2, the collagen IV positive tissue area was 15.8 ± 5.4% and the laminin positive 
tissue area was 20.9 ± 6.7%.  
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Figure 6.2: 20x magnification of high grade serous ovarian cancer immunohistochemistry 
from a 63-year old study participant; (a) haematoxylin stain, (b) collagen IV stain, brown = 
positive tissue, blue = negative tissue, (c) laminin stain, brown = positive tissue, blue = 
negative tissue, (d) segmentation of haematoxylin stain for cell density measurement, (e) 
segmentation of collagen IV stain for area quantification. Yellow colour represents staining 
with optical density (OD) 0.270 to < 0.355. Red colour represents staining with OD >= 0.355. 
(f) segmentation of laminin stain for area quantification. Yellow color represents staining 
with optical density (OD) 0.270 to < 0.355. Red colour represents staining with OD >= 0.355.  
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There was a weak but statistically significant correlation between mean MTR and cell 
density, r = 0.48, P = 0.049. MTR correlated negatively with both collagen IV and laminin, r = 
-0.56, P = 0.02 and r = -0.61, P = 0.01 respectively. Tumour cell density did not correlate with 
collagen or laminin levels, r = -0.48, P = 0.053 and r = -0.34, P = 0.18. Collagen IV and laminin 
however correlated with each other, r = 0.61, P = 0.01. Figure 6.3 shows scatterplots of the 
correlations between: (A) cell density and MTR, (B) collagen IV and MTR, (C) laminin and 
MTR, (D) collagen IV and cell density, (E) laminin and cell density, (F) collagen IV and laminin. 
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Figure 6.3: Plots of (A) tumour cell density vs. tumour MTR, (B) percentage of collagen IV 
tissue area vs. tumour MTR, (C) percentage of laminin tissue area vs. tumour MTR, (D) 
percentage of collagen IV tissue area vs. tumour cell density, (E) percentage of laminin tissue 
area vs. tumour cell density, (F) percentage of collagen IV tissue area vs. percentage of laminin 
tissue area. 
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6.4 Discussion 
In this study, MTR was found to have a weak positive correlation with tumour cell density 
and negative correlations with the levels of the BM proteins, collagen IV and laminin in 
HGSOC. Tumour cell density did not correlate with collagen IV or laminin, indicating that cell 
density and BM integrity may be independently related to MTR. Collagen IV and laminin 
levels also correlated with each other, which was expected as they are both markers of BM 
integrity.  
The higher MTR of tumours with higher cell density may signify that there is a greater 
abundance of cellular macromolecules binding water and generating MTR signal in more 
cellular tumours. This suggests that intracellular macromolecules, rather than extracellular 
macromolecules, are playing a dominant role in generating the MTR signal in ovarian cancer. 
This is further supported by the fact that there was a negative correlation with the major 
macromolecular components of the BM and MTR.  
MTR as a non-invasive measure of tumour cell density and intracellular macromolecular 
concentration could be a useful biomarker for stratifying tumours, identifying aggressive 
disease and treatment response monitoring. It could be complementary to other methods 
to image cellularity such as DWI. The data presented here also suggests that future MTR 
studies in other organs should consider the influence of cellular density on the results 
obtained and that the MTR may not simply be a function of extracellular protein 
concentration but may also be influenced by other biological and physical factors. 
The inverse relationship found between MTR and collagen IV/laminin in the BM could 
reflect the breakdown of the BM by invasive cancers that are growing, replicating and 
producing more cells. The results of this study suggest that as macromolecules that bind 
water (either intracellular or extracellular or both) increase in tissue, the BM is broken 
down. The increase in macromolecules with BM membrane breakdown also appears larger 
than can be accounted for by an increase in cell density alone as the relationship of BM 
protein loss to MTR is stronger than the relationship of tumour cell density to MTR. These 
additional macromolecules may be extracellular molecules from new ECM structures or 
secreted peptides. 
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The measurement of BM integrity through MTR could potentially provide early information 
on changes to the tumour microenvironment and stroma that may be of prognostic and 
therapeutic significance in HGSOC. BM breakdown could indicate early metastatic processes 
and therefore give an indication of patient prognosis. The limitations of this study include 
the time delay between tissue sampling and imaging, during which cell density changes, BM 
changes and cancer progression could have occurred. Multiple hypothesis testing was also 
performed which if corrected for using the Bonferonni correction would cause the loss of all 
statistically significant (P < 0.05) correlations detected here. In addition the repeatability of 
MT imaging for ovarian cancer has not yet been shown in any published work that it has 
been possible to find. The repeatability of MT imaging however has been shown for other 
tissue such as in healthy breast (176) and brain (177). A study on the repeatability of MT 
imaging in ovarian cancer performed in the future could be used to help interpret the 
results found here. 
In conclusion, this work shows that MTR measurements in HGSOC may correlate positively 
with tumour cell density, and inversely with collagen IV levels and laminin levels. MT 
imaging could therefore be of clinical use in oncological imaging to measure cellularity and 
to detect the breakdown of the BM. These findings have the potential to be applied in 
predicting invasion and metastases in HGSOC lesions. Further work is now needed with 
larger patient samples to verify these results and to explore the longer-term relationship of 
MTR with HGSOC including the association with outcome, relapse, survival and distant 
cancer spread in patients. 
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Chapter 7 
 
Hyperpolarized carbon-13 magnetic 
resonance imaging in cancer 
________________________________ 
 
7.1 Cancer metabolism 
As healthy cells undergo the malignant transformation into cancer there is a change in the 
way they metabolise glucose.  Pyruvate is generated from glucose in normal tissue by 
glycolysis and this process of glycolysis is increased in most cancers: tumours have increased 
glucose uptake compared to normal cells (178). Glycolysis is an irreversible chemical process 
involving ten enzyme-catalyzed reactions. The overall reaction is: 
 
C6H12O6 +2[NAD]+ + 2[ADP] + 2[P]I                       2CH3COCOOH + 2H+ + 2[NADH] + 2[ATP] 
 
After glycolysis, the pyruvate produced from glucose can enter one of three major 
metabolic pathways that can be imaged with hyperpolarized carbon-13 MRI (HP 13C-MRI). 
In healthy normoxic cells the majority of pyruvate is converted by the pyruvate 
dehydrogenase enzyme complex (PDH) into acetyl-CoA which joins the tricarboxylic acid 
(TCA) cycle where it is used primarily for the manufacture of carbon dioxide, water, ATP, 
GTP and NADH. The NADH produced from the TCA is further metabolised in the electron 
transport chain (ETC) within mitochondria to produce more ATP and carbon dioxide. Some 
of the carbon dioxide produced in the TCA cycle and ECT dissolves in tissue water to 
produce ionic bicarbonate. This bicarbonate if produced by the tissue in large enough 
concentrations can be imaged and quantified with HP 13C-MRI. The Henderson-Hasselbach 
equation can be applied to tissue bicarbonate quantification using HP 13C-MRI to create 
maps of tissue pH. 
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In cancer cells compared to healthy cells, larger amounts of the pyruvate from glycolysis are 
converted by the lactate dehydrogenase (LDH) enzyme into lactate. The reaction catalysed 
by LDH is reversible and uses NADH or NAD+ as a cofactor, depending on the direction in 
which it flows. The reaction is: 
pyruvate + NADH             L-lactate + NAD+ 
In healthy cells the diversion of pyruvate metabolism towards lactate production usually 
occurs only when there is a shortage of oxygen because of impairment of oxidative 
phosphorylation in hypoxic tissue.  Cancer cells however generate large amounts of lactate 
even in the presence of oxygen, termed aerobic glycolysis or the Warburg effect, which is 
partly driven by the anabolic demands of the rapid cellular proliferation that they undergo 
(179) and by overexpression of LDH. 
Lactate levels build up within cancers (180) and this lactate is preferentially diverted 
towards cell growth and proliferation rather further metabolic breakdown to produce 
energy via molecules like ATP and NADH (181). Lactic acid production in cancer may also aid 
tumour invasion through acidification of the extracellular environment, which helps to 
break down and remodel extracellular matrix structures that would otherwise impair 
tumour growth. Lactate levels in tumours have a strong correlation with aggressiveness, 
metastatic potential and overall prognosis (182-184). HP 13C-MRI can measure lactate and 
LDH activity in tissue which can aid diagnosis of cancers and can be used for monitoring 
changes in cancer metabolic activity over time such as in response to treatment. 
The third major pathway of pyruvate metabolism that can be studied with HP 13C-MRI is the 
conversion of pyruvate to the amino acid alanine, catalyzed by the enzyme alanine 
transaminase (ALT). ALT activity is highest in hepatocytes and muscle cells. 
HP 13C-MRI of pyruvate labelled in the first carbon position can be used to image injected 
pyruvate and the lactate, bicarbonate and alanine produced from this pyruvate. The lactate 
measurement can investigate the extent of the metabolic shift of pyruvate metabolism in 
cancers towards lactate production. The biochemical changes that occur in tissue with 
malignant transformation are also likely to occur earlier than the structural changes that are 
detected by other forms of imaging such as CT or proton MRI. HP 13C-MRI may therefore 
offer an earlier and more sensitive means of identifying cancer formation. In addition, 
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biochemical changes occur more rapidly following successful response to therapy than 
conventionally imaged anatomical changes. The major metabolic pathways relevant to HP 
13C-MRI of pyruvate metabolism are summarized in Figure 7.1 below. 
 
  
Figure 7.1: Schematic representation of the metabolism of pyruvate. 
 
7.2 Biological factors that can affect the HP 13C-MRI signal 
There are a number of biological factors that may contribute to the overall HP 13C-MRI signal 
in pyruvate and lactate imaging. Tumor vascularity and perfusion for example could affect 
the delivery of pyruvate to the tissue, as HP 13C-pyruvate is injected into a peripheral vein 
during imaging and must be transported through the circulatory system to the tumour 
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location. Tumour activity of the enzyme LDH may then influence the rate of conversion of 
pyruvate into lactate. Transport of pyruvate into the cell is also likely to be a determinant of 
metabolism into lactate as LDH is a cytoplasmic enzyme. The transmembrane transporter 
for pyruvate is the monocarboxylate transporter (MCT) and expression of MCT by cancer 
cells may thus also influence the HP 13C-MRI signal. 
 
7.3 Lactate dehydrogenase in cancer 
LDH activity and expression is higher in most types of cancerous tissue. The increase in LDH 
activity facilitates more rapid exchange between pyruvate and lactate (185-187). In healthy 
tissue LDH normally experiences negative feedback from the reaction it catalyzes so that 
increased levels of lactate and an acidic environment inhibit the production of more lactate. 
In cancer however, the high expression of LDH along with the switching off of other key 
regulatory mechanisms overcomes this feedback inhibition and lactate levels can increase to 
very high amounts (180). 
The LDH enzyme is comprised of 4 subunits. Each of these subunits is one of two types: M 
(muscle) or H (heart). LDH-M and LDH-H are also called LDH-A and LDH-B respectively. The 
subunits of LDH combine into the four-unit LDH enzyme in different ways to produce five 
main isoforms (188). These isoforms each predominate in different types of tissue and it is 
the LDH-A subunit of LDH that is overexpressed in cancers (185, 186, 189, 190), including 
HGSOC. Table 7.1 below lists the LDH isoforms and the tissues in which they are primarily 
found. 
 
LDH isoform Subunits Distribution 
LDH-1 4H + 0M Heart, red blood cells and brain 
LDH-2  3H + 1M White blood cells and the reticuloendothelial system 
LDH-3 2H + 2M Lungs 
LDH-4 1H + 3M Kidney and pancreas 
LDH-5  4M + 0H Skeletal muscle and liver 
 
 
Table 7.1: The main human LDH isoforms and their locations in the human body.  
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Although LDH is a cytoplasmic enzyme, serum levels may rise in certain forms of cancer 
where there is a leakage of intracellular contents into the extracellular space, for example 
from necrosis or where there is high tissue turnover such as in lymphomas. Serum LDH also 
increases when there is tissue damage or breakdown after chemotherapy treatment, and in 
conditions with cell lysis not related to cancer, including myocardial infarction, haemolytic 
states and after heavy exercise. A rise in serum LDH levels is sometimes used as a clinical 
biomarker in oncology along with electrolyte changes for tumour lysis syndrome. 
 
7.4 Monocarboxylate transporter expression in cancer 
The changes in metabolism that occur in cancer cells cause a high production of lactic acid in 
the intracellular space. Unless excreted or metabolised, lactic acid can build-up to such an 
extent that it could lower intracellular pH which could adversely affect the activity of 
enzymes that are sensitive to pH and the equilibrium of chemical reactions necessary for 
vital cellular processes. To prevent this happening, cancer cells have adapted to remove 
excess lactate by up-regulation of the expression of the monocarboxylate transporter 
(MCT). The efflux of lactate is essential to prevent a build-up of toxic levels inside cancer 
cells and the expression of MCT is believed to be higher in cancer partly for this reason 
(191). 
The MCT transmembrane protein can also transport pyruvate in addition to lactate across 
the cell membrane (192, 193) and the expression of MCT has previously been shown to be 
the rate limiting step in the conversion of extracellular pyruvate to lactate in breast cancer 
cells (194). 
Each of the four subtypes of the MCT transporter 1-4 exhibits different kinetics and 
substrate specificity. All MCT transporters facilitate the proton-linked movement of 
monocarboxylates such as L-lactate, pyruvate and ketone bodies in both directions across 
the plasma membrane. MCT1 is distributed widely across many different types of tissues 
and is best adapted for the transport of lactate into cells. MCT4 is more common in white 
skeletal muscle and works best at lactate export from cells. Both MCT1 and MCT4 are more 
prevalent in cancer.  
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7.5 Clinical hyperpolarized carbon-13 cancer imaging 
Pyruvate is transported rapidly into cancer cells because of MCT upregulation and is used 
more avidly by cancer cells because of changes in metabolism due to increased LDH levels 
and the Warburg effect. During the development of hyperpolarized imaging, 13C-labelled 
pyruvate emerged as the leading candidate molecule for cancer imaging (195, 196). The fast 
rate of production of lactate from pyruvate by high LDH activity in tumours and physical 
properties of the pyruvate molecule which help it to retain polarization during the lifetime 
of an in vivo experiment allow for sufficient hyperpolarized 13C-lactate signal to be retained 
upon injection of 13C-pyruvate to permit imaging before the hyperpolarized state decays. 
Genetic risk factors for ovarian cancer are of special interest in hyperpolarized imaging. This 
is because it is known that certain mutations affect the biochemistry of cancer cells through 
changes in the expression of proteins that influence key chemical reactions of metabolism 
such as those in the TCA cycle and electron transport chain (197-200). Proteins that are 
upregulated in cancer include the transporters (201, 202) and enzymes (185, 203) that 
transport and catalyze pyruvate and lactate. Comparing the presence of common mutations 
with hyperpolarized 13C-MRI could therefore potentially uncover correlations between the 
genetic composition of cancer tissue and imaging. 
Key proof-of-principle studies carried out at Cambridge have demonstrated that 
hyperpolarized 13C-pyruvate, hyperpolarized 13C-lactate and their exchange could be imaged 
in vivo in murine models and that early tumour biochemical responses to chemotherapy 
drugs could be detected in mice with implanted lymphomas (204). Hyperpolarized imaging 
is capable of detecting tumours and the changes that occur to the metabolism of pyruvate 
in some animal cancers as early as 24 hours after chemotherapy treatment (205). 
The first human trial to use hyperpolarized 13C-pyruvate was completed in 2013 by a group 
at the University of California San Francisco (UCSF) with a prototype clinical hyperpolarizer 
device. This group successfully imaged the metabolism of pyruvate in patients with prostate 
cancer. Areas with lactate accumulation were detected on hyperpolarized imaging that were 
not visible with proton MRI and some of these areas were shown by biopsy to contain 
tumour (206). These results provided initial evidence that hyperpolarized imaging could be 
more sensitive at detecting human cancers than traditional proton MRI. One of the next 
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steps in clinical hyperpolarised imaging with carbon-13 is to apply the technique to a disease 
where current detection and screening methods are inadequate such as ovarian cancer so 
that the imaging can be used to help improve patient outcomes. 
Higher grades of cancer are related to higher hyperpolarized lactate signal (207). HGSOC 
may therefore produce a larger and more easily detectable hyperpolarized 13C imaging 
signal than other cancers, that can be used to more accurately model enzyme kinetics. High 
grade serous ovarian malignancies also respond differently to chemotherapy in different 
patients (208) and no reliable method currently exists for detecting a response before 
several weeks of treatment have passed HP 13C-MRI could help address these clinical 
problems in HGSOC. 
The procedure involved in clinical carbon-13 hyperpolarization has been refined since its 
inception and General Electric (GE) Healthcare have developed commercial equipment 
termed SPINlab® to more efficiently carry out the process in a routine radiology enviroment. 
The SPINlab® includes quality control checks to ensure the safety of samples for human use 
and performs automated dissolution into an injectable form. 
A special sterile fluid path has been designed by GE Healthcare for use with the SPINLab®. 
The path is a single use, disposable unit and contains multiple components required to 
hyperpolarize a sample for human. The path must be assembled and filled in a sterile 
environment such as in a pharmacy facility under a laminar flow hood. The sample vial 
contains a mixture of the 13C molecule to be hyperpolarized and EPA (electron paramagnetic 
agent or radical). After filling the sample vial is sealed with a laser welder and the setup is 
placed in the SPINLab® for hyperpolarization. A picture of the GE Healthcare SPINlab at 
Cambridge is shown below in Figure 7.2 (a) and a picture of a clinical fluid path is shown in 
Figure 7.2 (b). A dedicated pharmacy unit was also built at Addenbrooke’s Hospital in 
Cambridge to assemble clinical fluid paths. 
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. 
The time available for imaging an injected hyperpolarized 13C molecule is limited because 
the half-life of the hyperpolarized state once dissolution has occurred is around 60 seconds 
and sufficient signal for imaging is only present for around 5 half-lives. During this short 
timeframe in addition to completing the imaging acquisition, the dissoluted solution must 
be transferred to the patient, injected into a peripheral vein, be transported by the 
circulatory system of the patient to the area being imaged and undergo metabolism in that 
tissue. In its current form hyperpolarized 13C-MRI is therefore only suited to imaging rapid 
chemical reactions. Reproducibility and repeatability of the technique in a clinical setting 
has not yet been demonstrated and because there is a lack of understanding of the 
underlying biological mechanism of signal generation, the interpretation of imaging results 
is also difficult. Current research is therefore still concentrated around proof-of-principle of 
the hyperpolarized 13C-MRI for humans in a clinical setting. 
Hyperpolarised 13C-MRI is thought to have the potential to detect changes in cancer earlier 
than more conventional forms of proton MRI used in clinical practice that image tumour 
structure, as biochemical changes in the transformation of healthy tissue into cancer and in 
the response of cancer to treatment occur earlier than structural alterations such as tumour 
Sample 
vial 
Figure 7.2: (a) GE Healthcare SPINlab, (b) sterile clinical fluid path 
 
a b 
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size that might be measured by criteria like RECIST on CT or MRI (209-213). Despite its 
clinical potential the quantification of pyruvate and its metabolites in tissue using 
hyperpolarised 13C-MRI is challenging due to the low concentrations of these metabolites, 
the larger number of biological covariates that can affect imaging signal and the difficlty of 
validation with tissue measurements due to the complexity of halting chemical reactions in 
biological systems for ex-vivo metabolite measurement. 
 
7.6 Imaging sequences, kinetic modelling and repeatability 
For clinical imaging, an IDEAL spiral or an echo planar imaging (EPI) pulse sequence may be 
used to rapidly image hyperpolarized 13C molecules. IDEAL uses spectral-spatial encoding 
based on single shot spiral encoding and was one of the first pulse sequences to be applied 
clinically for chemical shift imaging of hyperpolarized carbon-13 molecules. Both spiral 
imaging and EPI accelerate chemical shift imaging by performing spatial encoding between 
spectral sampling (214). A simplified depiction of the difference in k-space filling between a 
spiral acquisition and the more conventional EPI is shown in Figure 7.3 below. IDEAL has the 
advantage over EPI that it more uniformly samples data and provides less of a strain of 
hardware to produce gradients that rapidly switch in direction for the filling of k-space. One 
disadvantage of IDEAL is that is slightly slower than EPI and as spiral sequences are less 
frequently used than EPI, software that uses the IDEAL spiral is not as readily available, or 
easy to produce and implement at sites with low levels of physics support (215). 
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Figure 7.3: k-space filling using (A) spiral trajectory, (B) echo planar imaging. 
 
Pyruvate-lactate exchange in HP 13C-MRI may be modelled by fitting kinetic parameters to 
two-site exchange models or more simply with measurement of area under the curve (AUC) 
of the pyruvate-to-lactate ratio. Two-site exchange models assumes that the backward flux 
of lactate into pyruvate is zero and may be sensitive to the initial value of parameters in the 
model (216) and AUC models have the advantage of being independent of the shape of 
pyruvate inflow (217). Until there is a better understanding of the biological origin of the HP 
13C-MRI signal and larger human datasets however it will be difficult to determine which 
type of modelling is best for clinical use as the kinetics in the much larger human biological 
system is unlikely to be accurately represented by comparison studies performed on small 
animal models.  
At the time of writing this thesis there have been no published results on the repeatability 
or reproducibility of hyperpolarized carbon-13 MRI in humans using a clinical hyperpolarizer 
and a clinical imaging set-up. In preclinical experiments on mice implanted with lymphoma, 
the repeatability of hyperpolarized 13C-lactate to hyperpolarized 13C-pyruvate ratio 
calculated using fitting to the modified Bloch equation for two-site exchange no significant 
difference in the hyperpolarized 13C-lactate to hyperpolarized 13C-pyruvate ratio with repeat 
imaging was found (218). 
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Chapter 8 
Changes to ovarian cancer lactate 
dehydrogenase enzyme activity in response 
to treatment 
________________________________ 
 
 
8.1 Introduction 
In vitro tissue culture experiments are a valuable method for studying cancer by providing 
an opportunity to assess the effect of interventions on a genetically and phenotypically 
similar cell population, compared to in vivo experiments which include a mixture of cancer, 
stroma and other cell types and tissue structures.  
There are several well-established lines of ovarian cancer cells. Those commonly used to 
model ovarian cancer include OV, OVCAR and PEO. The suitability of a cell line for modelling 
the HGSOC subtype of ovarian cancer can be quantified by measuring properties such as the 
fraction of altered genome and the presence of gene changes that are specific to HGSOC. 
Such calculations have shown that OV is a poor representative of HGSOC while PEO and 
OVCAR are among the best (219). 
Animal experiments have shown that there is a decrease in the exchange between pyruvate 
and lactate in cancers after treatment  (12, 212). Anticancer treatments target cancerous 
cells and reduce the proportion of cells in a tumour with high LDH activity. The detection of 
treatment response with HP 13C-MRI however has never been shown to be possible for 
ovarian cancer either pre-clinically or in a human. In ovarian cancer there are new drug 
treatments currently being introduced clinically that may have a greater effect on LDH 
activity than traditional cancer treatments. Some ovarian cancers also carry the BRCA 
mutation which may further affect LDH activity. In this experiment the effect of different 
anti-cancer treatments on LDH expression in the PEO4 cell line was investigated.  
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8.2 PARP inhibitors in ovarian cancer 
PARP (Poly ADP-ribose polymerase) inhibitors are a class of ovarian anti-cancer drug that 
are of interest for hyperpolarized 13C imaging. PARP is an enzyme involved in the repair of 
single stranded DNA breaks. In cancer there is a higher rate of DNA replication errors and 
activity of PARP is important for repairing these errors. PARP activation leads to the 
cytosolic depletion of NAD+, as NAD+ is consumed to generate ADP-ribose monomers for the 
DNA repair process by base excision repair. NAD+ depletion causes NADH loss, as NADH is 
converted to NAD+ in response to low NAD+ levels. Significant PARP activation leads to cell 
death and glycolytic inhibition due to lack of NAD+/NADH and it has been shown that this 
cell death can be prevented when exogenous NAD+ is added to PARP (220, 221). In 
preclinical experiments on mouse lymphoma cells the chemotherapy drug etoposide was 
shown to deplete the NADH pool and reduce pyruvate-lactate exchange as measured with 
dynamic hyperpolarized carbon-13 magnetic resonance spectra. In the same set of 
experiments, it was demonstrated that the administration of the PARP inhibitor 
nicotinamide inhibited the etoposide induced NADH depletion. Nicotinamide along with 
another PARP inhibitor, 3-amino-benzamide, have also both been shown to inhibit 
etoposide-induced loss of pyruvate-lactate exchange (204). Neither of these drugs are 
clinically used PARP inhibitors however. 
PARP inhibitors (PARPi) cause cancer death by blocking the PARP enzyme from repairing 
DNA, leading to the accumulation and buildup of DNA damage to fatal levels in cancer cells. 
PARP inhibitors also lessen the depletion of NAD+/NADH in cancer tissue that would 
otherwise occur with PARP activation. When PARP inhibitors are used, there is more 
NAD+/NADH available in cancers to act as a co-factor in other chemical reactions such as the 
LDH catalyzed redox reaction that interconverts pyruvate and lactate. It was therefore 
hypothesized in this study that HP 13C-MRI may be able to image the biochemical effect of 
PARPi on cancer cells. 
PARP inhibitors are most effective for the treatment of ovarian cancers with BRCA 
mutations and their efficacy is being explored in on-going clinical trials (222, 223). Cancers 
with the BRCA mutation are unable to perform homologous recombination to repair double 
stranded DNA damage. When BRCA mutant cancers have the PARP enzyme inhibited they 
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are also unable to repair single stranded DNA breaks. The inability to repair single stranded 
DNA breaks provides the opportunity for the single breaks to progress into double stranded 
breaks which BRCA-mutant cells are unable to repair. Double stranded DNA breaks 
contribute to the threshold of fatal DNA errors that are required for cell death. A schematic 
showing the action of PARP and PARPi is shown below in Figure 8.1. 
 
Figure 8.1: Schematic showing the role of PARP and PARP inhibitor function in cancer cells 
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The use of PARP inhibitors is being studied in many tumours. Significant tumour responses 
and clinical benefit have been demonstrated with the PARP inhibitor olaparib in phase 1 
trials (223).  Olaparib given to patients with recurrent disease, after platinum-based 
treatment resulted in an improvement in progression-free-survival (PFS), and few toxic 
effects after prolonged administration (224).  
BRCA1 and BRCA2 are mutated in 6% and 9% of HGSOC cell lines respectively (225). Similar 
to PARP, BRCA uses NAD+/NADH in DNA repair. The depletion of NAD+/NADH with BRCA 
activity is not as extreme as with PARP activity. It is possible however that if HP 13C-MRI can 
detect the NAD+/NADH caused by PARP then it may be able to detect similar changes 
related to BRCA. 
To investigate whether HP 13C-MRI could image the effect of PARP inhibitors in ovarian 
cancer, cell experiments were performed where ovarian cancer cells were treated with 
olaparib and LDH activity was measured. The long-term goal was to understand the 
metabolic changes that occur in ovarian cancer following treatment including PARPi and 
how this can be applied to human imaging in the future. 
 
8.3 Cell experiment: Methods and materials 
 
Cell Growth and Treatment 
The PEO1 cell line was selected for this experiment because the BRCA1 mutation is 
universally present in PEO1 cells making this cell line responsive to PARP inhibitors. PEO1 is 
an adherent cell line. It was derived in 1988 from the malignant peritoneal effusion of a 
patient with ascites from a poorly differentiated serous adenocarcinoma of the ovaries. The 
patient the cells were extracted from had received treatment with cisplatin, 5-fluorouracil and 
chlorambucil before the cell extraction (226). PEO1 cells are very sensitive to oestrogen and 
the line has been used for many years in ovarian cancer research as a model to investigate the 
action of oestrogen on ovarian tumour cells. 
The PEO1 cells used in this study were obtained from frozen storage at -80 °C at the Cancer 
Research UK, Cambridge Institute. They were defrosted and grown using DMEM (Dulbecco's 
Modified Eagle Medium) containing L-glutamine that was mixed with foetal calf bovine 
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serum and penicillin + streptomycin antibiotic. The cells were placed in an incubator at 37°C 
until there were four confluent T-160 cell culture flasks. At confluence the cells were 
counted and a viability check was carried out on a small aliquot with Trypan blue. Counting 
was performed manually using a haemocytometer and light microscope as well as by 
electronic cytometry. Each flask was found to contain between 17.9 and 18.2 million cells 
with an average viability of 93.9%. The cells were re-suspended in media and 50,000 cells 
placed into each of the wells of 16 six-well plates. The 16 plates were divided into 4 sets of 4 
plates and each set was treated with different ovarian cancer chemotherapy drug to 
produce 4 sets of 24 identically treated wells. The four treatments were carboplatin, 
paclitaxel, olaparib and no chemotherapy. See Figure 8.2 for a schematic of the 
experimental design. 
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Figure 8.2: Schematic of ovarian cell experiment design. 
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Drugs were added in amounts that would result in a concentration in the wells equal to the 
inhibitory dose 50 (ID50) of each drug for PEO1 cells. Carboplatin was dissolved in distilled 
water and paclitaxel and olaparib were both dissolved in DMSO. The doses used were; 
• ID50 Carboplatin for PEO1 = 4 µM 
• ID50 Paclitaxel for PEO1 = 10 nM 
• ID50 Olaparib for PEO1 = 5 µM  
 
Drugs were obtained from the sources lister in Table 8.1 below.  
Drug Manufacturer Product Number 
Carboplatin Sigma-Aldrich C2538 
Paclitaxel Sigma-Aldrich T1912 
Olaparib BioVision 1952-5 
 
 
The volume of drug containing solution added to the wells to produce the desired treatment 
concentration was very small in comparison to the volume of media already in the wells (4 
ml). It was therefore assumed that the drug solutions did not significantly change the 
concentration of any other substances present in the wells. Volumes of drugs added to the 
wells are summarized in Table 8.2. 
 
Volume of media in wells 4.00 mL 
Volume of carboplatin solution added 0.355 µL 
Volume of paclitaxel solution added 4.44 µL 
Volume of olaparib solution added 2.22 µL 
 
 
Measurements were made of the intracellular and extracellular lactate concentrations and 
LDH activities using 6 wells from each set of 24 every day for 4 days. 
Table 8.1: Chemotherapy drugs used in cell experiments 
Table 8.2: Volumes of drug solution added to wells. 
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Lactate and LDH extraction 
Extracellular lactate and LDH measurements were acquired using media taken from the 
wells. For each well, approximately 2 mL of media was removed using a pipette and placed 
in a 15 mL falcon tube. The samples were rapidly frozen in dry ice to stop any further 
chemical reactions and transferred to a -80°C freezer for storage.    
To obtain intracellular samples, the cells were detached from the well with 1 mL of 0.25% 
trypsin. The trypsin was neutralised in 3 mL of media and the cells centrifuged in a 15 mL 
falcon tube at 1300 rpm for 4 minutes. The supernatant was discarded and the cell pellet 
lysed in 500 µL of ice cold LDH lysis buffer obtained from the Sigma-Aldrich LDH enzyme 
activity measurement kit (MAK066), according to manufacturer instructions. The resulting 
mixture was centrifuged at 3000 rpm for 15 min to remove the cell fragments and 350 µL of 
the supernatant was moved to a 15 mL falcon tube and rapidly frozen at -80°C.  
 
Measurement of lactate and LDH 
The frozen extracellular and intracellular samples were transported on dry ice to the CBAL 
(Core Biochemical Assay Laboratory) at Addenbrooke’s hospital for measurement of lactate 
and LDH. CBAL uses spectrophotometry of NADH at 340 nm to calculate lactate. LDH levels 
are found through biochromatic measurement of the rate of NADH production at 340 nm 
and 700 nm. The specifications for the assays and equipment provided by CBAL are given 
below in Table 8.3 and Table 8.4. 
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Table 8.3: Lactate assay specifications 
 
 
 
 
 
 
 
 
 
 
 
Assay Lactate  
Reagent 
Manufacturer 
Siemens Healthcare Diagnostics 
Assay Description 
 
Colorimetric assay using lactate dehydrogenase to catalyse the 
oxidation of lactate to pyruvate with the simultaneous reduction 
of NAD+ to yield NADH which absorbs at 340nm. Hydrazine is used 
to trap the pyruvate produced thus driving the reaction to 
completion. Lactate concentration is measured bichromatically as 
an end point at 340 and 383nm. 
The assay is automated on the Siemens Dimensionâ RxL analyser. 
The assay uses 4µl of sample. 
Calibration 
 
A series of BSA-based lyophilised assay calibrators are supplied by 
Siemens. 
Units Of 
Measurement 
mmol/L 
Lower limit of 
detection 
0.3 mmol/L (manufacturer’s data) 
Imprecision Data Between batch imprecision; 3.2% at 3.2 mmol/L , 1.9% at 10.4 
mmol/L, (manufacturers data). 
Reference Siemens Dimension Lactate kit insert, product DF16, issued 2015-
01-03 
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Assay Lactate Dehydrogenase (LDH)  
Reagent 
Manufacturer 
Siemens Healthcare Diagnostics 
Assay Description 
 
Colorimetric assay using the substrate L-lactate buffered at a pH of 
9.4 which is cleaved by lactate dehydrogenase in the presence of 
NAD+ to yield pyruvate and NADH which absorbs at 340nm. LDH 
activity concentration is measured bichromatically as a rate 
reaction at 340 and 700nm. The method is standardized against the 
International Federation of Clinical Chemistry (IFCC) LDH primary 
reference method procedure at 37oC adapted to the Dimensionâ 
clinical chemistry system. The assay is automated on the Siemens 
Dimensionâ RxL analyser. The assay uses 8µl of sample. 
Calibration 
 
A series of serum-based lyophilised assay calibrators are supplied 
by Siemens. 
Units of 
Measurement 
U/L 
Lower limit of 
detection 
6 U/L (manufacturer’s data) 
Imprecision Data 
 
Between batch imprecision; 2.8% at 113U/L, 1.1% at 376U/L, 
(manufacturers data). 
Reference Siemens Dimension LDI kit insert, product DF54, issued 2012-11-
07 
 
Table 8.4. Lactate dehydrogenase enzyme assay specifications 
 
8.4 Results  
Cell Number 
50,000 cells were used to seed each well so cell number started at 50,000 at Day 0 in all 
wells. The untreated wells went on to have the highest mean cell numbers at all subsequent 
time-points compared to the chemotherapy treated wells. Numbers in the carboplatin and 
olaparib wells went up with time and the numbers in the paclitaxel wells went down. Figure 
8.3 depicts the pattern of cell growth.    
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Total extracellular lactate 
Extracellular lactate was measured as a surrogate of overall metabolic activity as lactate is a 
waste product of normal metabolism. The lactate rose with time in all treatment groups and 
at the end of 4 days, the olaparib group had the highest extracellular lactate levels even 
greater than the control cells. Figure 8.4 shows the mean extracellular lactate at each 
timepoint in each group.   
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Total extracellular lactate per cell 
Given that lactate levels are a function of cell number in addition to their relationship with 
metabolic activity, the extracellular lactate levels were corrected for cell number, this is 
shown in Figure 8.5. In the carboplatin and control groups, extracellular lactate levels were 
stable suggesting that lactate may be a function of cell number in the presence of no 
treatment or of treatments which did not alter cell number significantly.  
Other factors besides cell number which may be influencing extracellular lactate values in 
these groups include cell death or a change in LDH activity due to drug action.  
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Intracellular LDH 
Mean intracellular LDH activities corrected for cell number are shown in Figure 8.6. The 
olaparib group was the only group to show a consistent rise in LDH over time (Student’s t-
test, P < 0.0001 for a difference between day 0 and day 4). The LDH activity rose in the 
olaparib to much higher levels than in the other treatment groups or the control group by 
Days 3 and 4 (Student’s t-test for Day 3: olaparib vs. carboplatin, P = 0.0002. Day 3: olaparib 
vs. paclitaxel, P = 0.0025. Day 4: olaparib vs. carboplatin, P = 0.0008. Day 4: olaparib vs. 
paclitaxel, P < 0.0001). LDH activity measurements were also made from the supernatant of 
these cell lines but these measurements did not show any significant changes over time 
with different chemotherapy drugs. 
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8.5 Discussion 
These preliminary in vitro results show that olaparib and paclitaxel at the doses used here 
are effective in preventing cell growth in PEO1 cells. In both treatments this inhibition is 
associated with a rise in extracellular lactate when corrected for cell number which may be 
driven by oxidative stress or cell death. In the case of olaparib the inhibition of cell number 
progression is also associated with an increase in LDH activity compared to the other 
ovarian cancer therapies. The raised LDH activity in the olaparib group may partially explain 
the elevated extracellular lactate demonstrated in this group of cells however, as LDH was 
not elevated in the paclitaxel group, other mechanisms are likely to also contribute to the 
elevated extracellular lactate. Other factors that may contribute to elevated extracellular 
lactate include; elevated intracellular lactate, alterations in the concentration of NAD(H), 
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changes in MCT expression, rapid cellular proliferation and cell death with release of 
intracellular contents into the extracellular environment. In this study, the intracellular 
lactate levels were low after cell processing for accurate measurement using the 
spectroscopic methods employed here so the effect of intracellular lactate on extracellular 
lactate concentration could not be assessed. 
Except for the olaparib group, intracellular LDH activity remained stable over time when 
corrected for cell number. The response of LDH to olaparib in these experiments appears to 
occur by Day 2. By Day 4 the activity rose in the olaparib group to almost double that of the 
untreated cell group. PARP inhibitors may increase LDH activity and lactate concentration by 
increasing NAD+/NADH levels. This is contrary to the effect seen with conventional 
chemotherapy drugs and cell lines where successful therapy response is almost universally 
associated with a reduction in LDH activity as measured by a reduction in the exchange rate 
constant of hyperpolarized 13C-pyruvate to 13C-lactate or kPL (227). This finding could 
represent a potentially novel method of measuring response to targeted therapy. LDH 
activity measurements made from the supernatant did not show any significant changes 
over time of between chemotherapy treatments and this may reflect the low levels of 
extracellular LDH in comparison to the intracellular fraction or could be due to enzyme 
degradation or inactivation during extraction. 
 
8.6 Conclusions and future work 
This data has shown that changes in extracellular lactate occur in ovarian cancer cell lines 
over time following treatment and that these may be used for monitoring therapy response. 
They also show that PARP inhibitors may cause alterations to LDH related to their mode of 
action in preventing depletion of NAD(H), which as a co-factor for the enzyme LDH can be 
probed with hyperpolarized carbon-13. 
Hyperpolarized imaging of lactate formation in patients undergoing PARP inhibitor 
treatment could help improve our understanding of the mechanism of action of PARP 
inhibitors in vivo and may be able to detect an early response to PARPi treatment because 
of the increase in LDH activity. The LDH response in cells seems to occur at 2-3 days post-
treatment and this finding agrees with previous studies using other cell lines and tumour 
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models although that have shown a decrease in hyperpolarized 13C-lactate signal around 
this time period following treatment (228) . The precise timing of the response in patients in 
the clinical setting would be expected to vary from the timing in cells experiments on pure 
cell lines, given the complex tumour microenvironment of cancers but future experiments 
with further cell lines, later time points, additional chemotherapy drugs and alternative 
doses may help improve understanding of the initial results found here. 
The findings of these experiments support the translation of HP 13C-MRI into ovarian 
cancers, particularly in the context of ovarian cancer and the potential for HP 13C-MRI to 
non-invasively detect BRCA mutation could lead to further clinical applications in genetics 
and therapeutics for this imaging technique.  
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Chapter 9 
 
Case report on hyperpolarized carbon-13 
MRI and combination 18F-FDG-PET/MRI in 
an ovarian tumour 
 
 
9.1 Background 
18F-FDG-PET and hyperpolarized carbon-13 MRI (HP 13C-MRI) both image tissue metabolism 
but they do so in different ways and provide different information on tissue function. 18F-
FDG-PET probes the spatial distribution of 18F labelled compounds in tissue and cannot 
distinguish between the chemical compositions of the different molecules that carry the 
radioactive 18F label. By comparison HP 13C-MRI uses chemical shift information from 
spectroscopy to identify different metabolites of the 13C tracer and is sensitive to the carrier 
molecule to which the 13C is attached. HP 13C-MRI and 18F-FDG-PET also look at different 
steps in the metabolism of glucose, different enzyme activities and different transporters. 
Figure 9.1 summarises some of the differences in the metabolic pathways probed by 18F-
FDG-PET and HP 13C-MRI. 
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Figure 9.1: Metabolic pathways that can be studied with 18FDG-PET (red) and HP 13C-MRI 
(green) 
 
 
 
When used together, 18F-FDG-PET and HP 13C-MRI provide complementary information to 
each other and give a more complete picture of the metabolism of glucose in vivo than 
either form of imaging on its own. Simultaneous 18F-FDG-PET and HP 13C-MRI, termed 
hyperPET, has been performed in a canine cancer model and has shown that HP 13C-MRI is 
more specific for the Warburg effect, while 18F-FDG-PET could not differentiate between 
increased glucose uptake from the processes of oxidative phosphorylation and glycolysis 
(229). 
18F-FDG-PET imaging has a low spatial resolution and must be combined with anatomical 
imaging from CT or MRI to give meaningful clinical information. Clinical 18F-FDG-PET imaging 
is most often combined with CT as this provides adequate anatomical information, simple 
and accurate attenuation correction and is cheaper, faster and more accessible than MRI. 
MRI has the advantages over CT when combined with 18F-FDG-PET however that it does not 
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add to the radiation exposure of the patient and provides multiple additional forms of tissue 
contrast. When used with HP 13C-MRI, the combination of 18F-FDG-PET/MRI can be more 
accurately co-registered and compared to the HP 13C-MRI images than co-registration with 
18F-FDG-PET/CT. Furthermore, HP 13C-MRI has great potential to provide novel and 
complementary information on metabolism when combined with 18F-FDG-PET. 
There are no published examples of the combination of a HP 13C-MRI and 18F-FDG-PET/MRI 
scan in a human. To investigate the feasibility of this combination of imaging and the 
differences that can be detected between HP 13C-MRI and 18F-FDG-PET in a human, a patient 
with an ovarian mass was imaged with both HP 13C-MRI and 18F-FDG-PET/MRI as part of this 
PhD for the first time. HP 13C-MRI derived metabolite maps and SUVmax values from the 18F-
FDG-PET scan for different tissue types were then compared to each other and the surgically 
extracted tissue from the patient was analyzed to obtain information on the biological 
factors that affect the signal in HP 13C-MRI. 
 
9.2 Methods 
Study design 
The HP 13C-MRI and 18F-FDG-PET/MRI imaging of a patient with an ovarian tumour 
preformed for this work were completed as part of the MISSION-ovary (Molecular Imaging 
and Spectroscopy with Stable Isotopes in Oncology and Neurology - ovary) study.  
 
Clinical details of patient 
A 70-year-old woman with an ovarian mass was recruited for HP 13C-MRI and 18F-FDG-
PET/MRI imaging. The patient first presented to her general practitioner (GP) after noticing 
a purple discolouration around her umbilicus. US at that time revealed a large soft tissue 
mass and further evaluation was carried out with a CT scan. 
 
CT confirmed a large complex soft tissue mass in the midline of the abdomen appearing to 
arise in the pelvis from the right ovary and which measured a maximum of 187 x 136 mm in 
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axial dimensions. Multiple areas of calcification were also noted superiorly and there was a 
moderate volume of ascites. No definite discrete peritoneal deposits or omental cake could 
be identified. Images from the CT scan of the tumour are shown in Figure 9.2. The serum 
tumour marker and other blood results taken under the research protocol before imaging 
are given in Table 9.1: 
 
 
Figure 9.2: CT scan of first HP 13C-MRI and 18F-FDG-PET/MRI case. (a) axial image, (b) coronal 
reformatted image, (c) sagittal reformatted image.  
 
 
 
 
 
 
 
 
 
 
a b c 
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Serum marker Result Normal range Units 
CA125 (carcinoma antigen 125) 473  0-35 U/L 
CEA (carcinoembryonic antigen) 1.9  0.0-5.0 µg/L 
AFPT (alpha fetoprotein) 3  0-10 kU/L 
Intact hCG (human chorionic gonadotropin) 4.4  0.0-4.0 U/L 
Free hCG (human chorionic gonadotropin) <0.2  0.0-0.2 U/L 
Oestrogen 98  <118 pmol/L 
FSH (follicle stimulating hormone) 37.6  21-140 U/L 
Glucose 5.4  - mmol/L 
Lactate 2.3  0.1-1.8 mmol/L 
LDH (lactate dehydrogenase) 143  100-190 U/L 
ALT (alanine transaminase) 13  7-14  U/L 
 
Table 9.1: Blood test results for the first hyperPET patient. 
 
After discussion at the MDT, primary surgery was scheduled to obtain a histological 
diagnosis. The patient was recruited to MISSION-ovary prior to surgery despite no 
histological diagnosis based on an RMI score at recruitment of 3 (complex mass and ascites 
on US) x 3 (post-menopausal score) x 473 (CA-125 level in U/L) = 4257, corresponding to a 
high chance of malignancy (RMI score > 200). The patient was also found to have other 
serum tumour marker results that were consistent with HGSOC (see Table 9.1). The 
subsequent post-operative histology after the MISSION-ovary research study imaging had 
been performed in this patient however showed that this lesion was a fibroma which was an 
unlikely finding giving the pre-operative diagnostic test results.   
 
18F-FDG-PET/MRI imaging  
18F-FDG-PET/MRI scanning was performed on the patient five days before surgery using a 3 
T PET-MR scanner (Signa, GE Healthcare, Waukesha WI) at the Wolfson Brain Imaging 
Centre (WBIC), Cambridge Biomedical Campus, Cambridge. The patient was fasted for 12 
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hours prior to her 18F-FDG-PET/MRI examination. After an uptake period lasting 60 min 
following intravenous injection of 4 MBq/kg 18F-FDG (Alliance Medical), the participant 
underwent the PET acquisition and simultaneous MRI which lasted 30 minutes and covered 
an anatomical area from just above the diaphragm to the mid-thigh.  
A single blood sample was acquired immediately prior to the 18F-FDG injection to measure 
plasma glucose concentration and other blood markers. PET/MR acquisition was performed 
in caudo-cranial direction using 3 bed positions (8 min/bed position) with the patient placed 
in the supine position. PET emission data were reconstructed into a 256x256 image matrix 
with 2.34x2.34x2.78 mm voxels, using time-of-flight ordered subsets expectation-
maximisation (TOF-OSEM) with 2 iterations and 28 subsets. Corrections for randoms, dead 
time, normalisation, attenuation, scatter and sensitivity and isotope decay were applied as 
implemented on the scanner by the manufacturer, together with a 6-mm FWHM Gaussian 
filter post reconstruction. MR for attenuation correction (MRAC) utilised the vendor-
supplied two-point Dixon sequence. T2-weighted proton MRI images were also acquired 
during imaging.  
 
HP 13C-MRI imaging technique 
HP 13C-MR was undertaken the day after PET imaging using a 3T MR system (MR750, GE 
Healthcare, Waukesha WI) in the Addenbrooke’s Hospital Magnetic Resonance Imaging and 
Spectroscopy unit. At the time of the PET imaging, it was not possible to acquire HP 13C-MR 
imaging on the PET/MRI system due to a Quality Control (QC) failure with the hyperpolarizer 
at the WBIC. 
Pharmacy kits/fluid paths for insertion into the clinical hyperpolarizer (SPINlab, 5T, Research 
Circle Technology, Niskayuna, NY) were filled under sterile conditions. 1.47g [1-13C]pyruvate 
acid (Sigma Aldrich, St Louis, Missouri, USA) containing 15 mM of an electron paramagnetic 
agent (EPA, Syncom, Groningen, Netherlands) was sealed in a vial; 38 mL sterile water was 
used for dissolution; 19 mL sterile water with 17.5 mL NaOH/Tris/EDTA (2.4%, 4.03%, and 
0.033% w/v respectively, Royal Free Hospital, London) was used as a buffer for 
neutralisation. Pharmacy kits were stored in a freezer at -20 °C for at least two weeks prior 
to use. The vial containing the frozen pyruvate/EPA mix was defrosted in the helium 
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pressurised airlock in the hyperpolarizer for one hour. The sample was irradiated at 139 GHz 
at ~0.8 K for approximately three hours. Following rapid dissolution, the pyruvic acid was 
neutralised with the buffer and QC checks were performed by an integrated QC module 
which measured: pyruvate and EPA concentration, pH, temperature, sample polarization 
and volume of dissolute. The release criteria for injection were: pyruvate concentration 220-
280 mM; radical concentration < 3 µM; pH 6.7-8.1; and temperature 25-37 ºC. QC checks on 
the dissoluted hyperpolarized 13C-pyruvate that was injected into the patient produced 
results of:  
 
Polarisation: 16.1% 
Pyruvate concentration: 265 mM 
EPA concentration: 0.8 µM 
pH: 7.2 
Temperature: 33.1°C 
Volume of pyruvate: >40mL 
 
After release from the QC, the HP 13C-pyruvate sample was passed through a radio 
frequency (RF) shielded hatch and injected with an automated Medrad pump set to deliver 
the injection at 5 mL/s and a dose 0.4 mL/kg (Medrad, Warrendale, Pennsylvania, USA). The 
hyperpolarized pyruvate injection was followed by a 25 ml 0.9% saline bolus infusion at 5 
mL/s to accelerate delivery of the pyruvate to the tumour. The actual volume of pyruvate 
injected into the patient was 27.9 mL and the time from dissolution to injection was 51s. 
A delay of 16 s was allowed for the pyruvate to undergo metabolism to lactate in the tissue. 
13C-MRSI (magnetic resonance spectroscopic imaging) was performed using an IDEAL spiral 
pulse sequence with nominal flip angle 20°, acquisition time 120 s, FoV 36 x 36cm, in-plane 
resolution 18 x 18 mm and five slices each 3.5 cm thick positioned across the pelvic mass 
with a 5 mm gap between the slices. Transmit Gain and center frequency (f0) were 
determined using a Bloch-Siegert method. A clamshell body coil from GE was used for RF 
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excitation and an 8-channel abdominal array from Rapid (Rimpar, Germany) was used as the 
receive coil. Five spectral peaks were imaged: 13C-pyruvate, 13C-lactate, 13C-pyruvate 
hydrate (the hydrated form of pyruvate which exchanges with the unhydrated form), 13C-
bicarbonate (produced from 13C-carbon dioxide catalysed by carbonic anhydrase in vivo) and 
13C-alanine. The spectra were recorded at 30 timepoints, each 4 s apart. Data were 
reconstructed using Matlab (The Mathworks, MA, USA). Time-averaged images of 13C-
pyruvate, 13C-lactate and 13C-bicarbonate over all timepoints were calculated for each slice. 
Reconstruction was preformed by Dr Mary McLean from Cancer Research UK and the 
University of Cambridge Department of Radiology. 
 
9.3 Results 
Figure 9.3 shows the 18F-FDG-PET/MRI imaging appearance for a slice through the mass. The 
18F-FDG uptake appeared spatially very heterogenous. SUVmax of the mass was 1.54. Figure 
9.4 shows the spectra and images of different 13C molecules. Summed metabolite maps are 
shown in Figure 9.5 with the corresponding 18F-FDG-PET images for comparison. Figure 9.6 
displays graphically the relationship of SUVmax to HP 13C-pyruvate signal for selected tissue 
types. 
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Figure 9.3: 18F-FDG-PET/MRI imaging. (a) Axial proton image through the pelvic mass, (b) 
sagittal section showing the level of the axial slice, (c) coronal section showing level of axial 
slice, (d) 18F-FDG-PET image, scale bar represents SUV values, (e) fusion of 18F-FDG-PET and 
proton MRI, scale bar represents SUV. 
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Figure 9.4: 13C-MRI slice positions shown on proton images (bottom) and dynamic spectra 
(top) imaged through the ovarian mass. 
 
Slice 1
Slice 4
Slice 3
Slice 2
Slice 5
132 
 
 
 
 
 
Figure 9.5: 13C-MRI metabolite maps showing the spatial distribution for pyruvate and 
lactate and the corresponding 18F-FDG-PET images. 
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Two approaches were used to evaluate the metabolism of the 13C-pyruvate: firstly a 
ratiometric approach of 13C-lactate-to-pyruvate (summed over the time course), as a simple 
surrogate for the exchange reaction. Secondly, a 2-site exchange model was used to 
calculate maps of kPL, the apparent exchange rate constant for the LDH reaction which also 
incorporates perfusion and transport as described by Khegai (230). Due to the very low 
lactate signal because the tumour was non-malignant these evaluations of metabolism 
failed to produce meaningful results as noise levels were similar to lactate levels making 
measurements unreliable. 
 
9.4 Discussion 
This work presents the first example of HP 13C-MRI of an ovarian mass in a human. There 
have been several pre-clinical studies which assessed the combination of FDG-PET and HP 
13C-MRI: for example, in vitro studies have shown that the treatment response 
measurements are similar for the two techniques in breast cancer models (231) and recent 
work has shown the feasibility of this imaging in canine cancer models (232). There is 
currently a single published human study that compared HP 13C-MRI with 18F-FDG-PET/CT in 
a glioma patient but not with 18F-FDG-PET/MRI  (233). The ovarian case presented here 
extends these previous pieces of work to show that the combination of 18F-FDG-PET/MRI 
and HP 13C-MRI is possible in a human for the first time. 
Ovarian cancer is metabolically active and well perfused and therefore a good model for 
studying cancer metabolism. The patient in this work was recruited onto the study due to a 
high suspicion for HGSOC but the lesion was unfortunately found to be benign after 
extraction at surgery. The uptake of 18F-FDG and the formation of 13C-lactate were much 
lower than was expected at recruitment due to the benign nature of the mass. Nonetheless, 
this work has demonstrated proof-of-principle that combined 18F-FDG-PET/MRI and HP 13C-
MR can be carried out in a clinical setting.  
The HP 13C-MRI data collected here was analysed both from spectra and from constructed 
images. On the summed spectra, there were peaks detected for 13C-pyruvate, 13C-lactate 
and 13C-pyruvate hydrate but not for 13C-bicarbonate or 13C-alanine. Although 13C-
bicarbonate is generated in healthy tissue such as the normal brain and heart where there 
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are high levels of PDH, it is rarely seen in tumours. 13C-alanine is detected in muscle and in 
the liver where there are high levels of ALT and was not expected to be found in an ovarian 
mass.  
There was sufficient signal in this case to generate 13C-pyruvate images which appeared to 
have reflected tissue perfusion. Although 13C-lactate images were produced (Figure 9.5), 
given the benign nature of the lesion, these demonstrated only low level 13C-lactate levels 
and the images were too noisy for detailed analysis such as with kinetic modelling to 
calculate kPL and 13C-lactate-to-pyruvate maps.  
Importantly however, there was a visible difference in the areas of uptake of 18F-FDG and 
13C-pyruvate signal both for tumour and for healthy tissue. This is a promising result which 
supports the possibility that 18F-FDG-PET and HP 13C-MRI measure different aspects of 
glucose metabolism and suggests that HP 13C-MRI may have a complementary role to 18F-
FDG-PET in metabolic imaging. For example, 18F-FDG-PET may measure GLUT transport and 
hexokinase activity for the first few steps in glycolysis whereas 13C-pyruvate may measure 
perfusion and MCT transport. 13C-lactate measurements in cases with better signal could 
also additionally probe the enzymatic steps glycolysis by assessing LDH activity. Further 
work is needed to identify which biological processes or properties of tissue are measured 
with HP 13C-MRI: this question can partially be addressed by tissue analysis following HP 13C-
MRI imaging. 
A quantitative comparison of 18F-FDG-PET and HP 13C-MRI could be carried out in the future 
in more metabolically-active tissue using a pixel-by-pixel image analysis approach; for the 
particular case used in this study, the uptake of both 13C-pyruvate and 18F-FDG-PET were low 
(tumour SUVmax = 1.54) as the mass was not a cancer, making it difficult to undertake such a 
direct comparison in the context of a low signal-to-noise ratio. Future work after this PhD is 
planned to address this through the recruitment of patients with confirmed HGSOC lesions 
that are more likely to be 18F-FDG avid, to produce high concentrations of lactate (234) and 
to have high LDH concentrations (235) which would more likely be detectable with 
hyperpolarized carbon-13 imaging.  
HP 13C-pyruvate imaging may also be improved in the future by applying a correction to the 
signal from the perfusion measurements derived using dynamic contrast enhanced (DCE) 
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MRI. For example, by making use of Ktrans (the volume transfer co-efficient and measure of 
capillary permeability) to adjust the hyperpolarized 13C metabolite and kinetic rate constant 
maps. The much smaller molecular weight of pyruvate compared to gadolinium contrast 
agents may also mean that HP 13C-MRI of pyruvate could be a more sensitive indicator of 
tissue permeability than DCE. 
In conclusion, HP 13C-MRI and 18F-FDG-PET were successfully performed on the same patient 
for the first time. Two previous attempts at HP 13C-MRI imaging in ovarian cancer patients at 
Cambridge failed. In the first case failure was due to dissolution into a solution of the wrong 
concentration for injection by the hyperpolarizer and in the second case the detector coil 
malfunctioned and prevented detection after injection of hyperpolarized 13C-pyruvate into 
the patient. The results of the successful scan indicate that combined HP 13C-MRI and 18F-
FDG-PET is feasible in a clinical setting. Further clinical studies are now needed to compare 
HP 13C-MRI with tissue analysis to identify the specific metabolic properties of tissue that 
the HP 13C-MRI molecules probe. In the future, the HP 13C-MRI technique demonstrated 
here could be used to stratify tumours based on metabolic phenotype, genetics like the 
presence of a BRCA mutation and to detect early treatment response as has already been 
demonstrated in animal models. 
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Chapter 10 
 
Magnetic resonance fingerprinting in 
ovarian cancer 
________________________________ 
 
10.1 Background 
Quantitative parameter mapping is a more reproducible method of imaging than many 
forms of contrast generated with MRI, as it is not as dependent on the performance of the 
scanner hardware. Quantitative maps however have traditionally taken a long time to 
produce due to the need to repeat imaging multiple times with different acquisition 
parameter values and this has limited clinical utility. Magnetic resonance fingerprinting 
(MRF) provides a method to significantly shorten scan times and could allow parameter 
mapping to become practical in a clinical setting.  
In MRF, a dictionary is created for each imaging session from a user prescribed set of 
imaging parameters usually derived from the Bloch equations such as T1, T2 and flip angle. 
Selection of imaging parameters for dictionary generation is based on the types of image 
reconstructions intended by the user. The greater the number of parameters that is 
included for dictionary creation, the longer it takes for the dictionary to be created and the 
greater the number of possible signal evolutions, which means more storage space is 
needed. 
MRF may produce images that have different sensitivity to tissue properties than 
conventional proton imaging sequences because of its use of a theoretical modelling of the 
signal with selected MR imaging parameters and may lead to improved detection of tissue 
heterogeneity which could in turn relate to disease progression (236).  While tissue 
heterogeneity can be detected on T1 and T2 weighted images, tissue heterogeneity from 
MRF may also be obtained more directly from quantitative maps which can be useful in the 
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rapidly evolving field of radiomics which at times aims to quantify heterogeneity on imaging 
(237). 
Because MRF can examine a large number of MR parameters in a short period of time, it 
may add value to the detection of lesions in tumours that are located in anatomical areas 
with diverse tissue types in the background such as the female pelvis.  As part of this PhD, a 
proof-of-concept study was designed where MRF was applied to the imaging of ovarian 
cancer and used to generate T1, T2 and PD maps to investigate whether MRF can be used 
provide information on the characterisation of ovarian masses in patients. Results from the 
work have been published in IEEE Transactions on Radiation and Plasma Medical Sciences 
(238). 
 
10.2 Methods 
Imaging 
Imaging was performed on a 3.0 T MRI system (MR750, General Electric, Milwaukee, WI, 
USA) using a 32-channel abdominal coil. All patients were imaged in the supine position. The 
MRI protocol consisted of standard qualitative clinical sequences followed by a 2D steady-
state-free-precession (SSFP) MRF sequence (239). 
The MRF data was acquired using 979 frames with golden-angle spiral k-space interleafs.  
The golden-angle interleafs enabled the repetition time and flip angle lists used to match 
the values in Jiang et al. (240, 241). Further sequence parameters were: field-of-view = 380 x 
380 mm2; matrix = 192 x 192; voxel size = 2.0 x 2.0 x 3.0 mm3; slice thickness = 3.0 mm; slice 
spacing = 1.0 mm; sampling bandwidth = ±250 kHz; TE = 1.8 ms; acquisition time = 15 
sec/slice; and TR was varied based on Perlin noise.  The max gradient strength per spiral was 
17 mT/m and the max slew rate was 62 T/m/s.  The gradient strength was limited to low 
maximum values to ensure that a large Nyquist FOV would be obtained to cover the whole 
abdomen. The scanner was operated by Dr Joshua Kaggie, an MRI physicist from the 
University of Cambridge Department of Radiology. 
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MRF Dictionary Simulation 
Dictionary simulations of SSFP signal evolutions were performed using the extended phase 
graph formalism. The detailed ranges and incremental (step-size) changes used for T1 and T2 
included in the dictionary are listed in Table 10.1.  This range was chosen to extend 
sufficiently for capturing both low relaxation values, which occur in dense tissue, and high 
relaxation values, which occur in highly fluidic regions such as ascites.  The increments were 
chosen to have higher densities near low relaxation values, where the increments 
correspond to a larger percentage change for each dictionary value. 
 
Parameter Range (ms) Increment (ms) 
T1 10 - 400 10 
 400 - 4000 20 
T2 2 - 20 1 
 20 - 400 2 
 400 - 2500 20 
 
Table 10.1:  Detailed ranges and incremental changes used for T1 and T2 in the dictionary 
 
MRF Reconstruction and Analysis 
After acquiring the data, each under-sampled spiral acquisition was reconstructed using a 
non-Cartesian FFT, resulting in 979 undersampled images. MRF uses a relatively simple 
pattern recognition algorithm to identify the tissue and its corresponding properties in each 
voxel. The inner products between the normalized measured signal evolution of each voxel 
and each normalized dictionary entry were then calculated with the dictionary entry 
returning the maximum value of the inner product, taken as the best representation of the 
acquired signal evolution and the respective T1 and T2 values are consequently assigned to 
the voxel. The proton density (PD) map was calculated as the scaling factor used to match 
the dictionary simulation with the measured signal evolution. Mean T1 and T2 values for the 
three tumour types were calculated in Matlab from regions-of-interest (ROIs) drawn using 
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software written in Python Language Reference (Python Software Foundation) version 2.7 
with Matplotlib on four consecutive slices. The ROI analysis was also preformed by Dr 
Joshua Kaggie. 
 
10.3 Results  
Four patients were imaged: one borderline serous, two untreated high-grade serous (one 
with peritoneal deposits plus ascites and the other with the cancer located primarily in the 
ovary), and one post chemotherapy HGSOC. The generated T1, T2 and PD maps of the four 
patients are shown in Figure 10.1. Mean T1 and T2 values and their standard deviations (SDs) 
estimated from ROIs for each tumour type are listed in Table 10.2. 
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Figure 10.1: MRF generated T1, T2 and PD map 
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Tumour type T1 (ms) T2 (ms) 
Borderline 2465 ± 101 225 ± 34 
HGSOC (ovarian location) 1975 ± 191 94 ± 15 
HGSOC (peritoneal deposits) 1621 ± 46 174 ± 26 
Post-treatment HGSOC 1059 ± 55 116 ± 12 
 
Table 10.2: MRF derived relaxation values of different ovarian tumour types 
 
 
 
10.4 Discussion 
 
Here we demonstrated the feasibility of using MRF for fast quantification of relaxation 
parameters in ovarian cancer. The borderline serous tumour had a higher T1 value than the 
two high-grade carcinomas, which were easily distinguishable from each other on the MRF 
maps. The patient post-treatment demonstrated lower T1 and T2 values compared to the 
other three patients with borderline or high-grade carcinoma. Mean T1 and T2 relaxation 
times of the borderline ovarian tumour were longer by ~20% and ~58%, respectively, when 
compared with the high-grade tumours.  
The sample size investigated here was small which makes it difficult to draw any definite 
conclusions from the findings. Further studies are required to confirm and verify these 
findings in a larger cohort and to demonstrate the robustness of the results. MRF-generated 
quantitative maps will also need to be compared to conventionally obtained parameter 
maps using a variable flip angle approach in the future. If these future comparisons validate 
MRF as a fast, reliable and enhanced alternative to the time-consuming “gold-standard” 
approaches, it could enable MRF to find a clinical role.  The MRF method used here could 
also be improved by increasing its resolution to detect smaller tumour lesions with higher 
accuracy. In addition to relaxation times, the MRF methodology employed in this study 
could be expanded with measurements of other tissue properties such as diffusion and 
perfusion to gain more information for an improved classification of tumour masses.  
In conclusion, this work is the first demonstration of MR Fingerprinting in ovarian cancer 
imaging in four subjects. The generated quantitative MRF maps in this proof-of-concept 
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work revealed that T1 and T2 differences can be detected and this could potentially be 
applied to better characterise tumour lesion. Further work is now needed to expand on 
these results by comparing the MRF generated maps with conventionally acquired T1, T2 and 
PD maps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
Chapter 11 
 
Conclusions 
________________________________ 
 
11.1 Summary of imaging findings in ovarian cancer 
Several novel imaging techniques to investigate ovarian cancer have been presented as part 
of this PhD dissertation and these have each been shown to provide information on 
different tumour properties, which could be of use clinically. DKI was shown to predict 
responders to cytotoxic drugs. 23Na-MRI was found to measure cellularity that could be 
applied to monitoring treatment response. MT imaging was found to be a possible 
biomarker of tissue cellularlity and basement membrane integrity. HP 13C-MRI of an ovarian 
mass was demonstrated for the first time and has the potential to give information on the 
metabolism of pyruvate, enzyme activity, transporter expression and genetic mutations in 
ovarian cancer. Finally, MRF was shown to provide quantitative parameter mapping that 
could improve imaging speed and reproducibility. Table 11.1 summarizes the pros and cons 
of each of the imaging techniques evaluated in this PhD.  
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Imaging technique Advantages Disadvantages Tissue information provided 
Diffusion kurtosis 
imaging (DKI) 
1. Uses conventional 
proton imaging set-
up 
2. Parameter maps 
can be constructed 
offline on a 
separate computer 
saving scanner 
time. 
 
1. Requires a scanner 
capable of high 
diffusion gradients 
2. Due to low SNR, 
requires 3T or 
higher scanner 
3. Longer scan time 
than for ADC 
mapping as images 
with larger number 
of b-values are 
required 
1. Measures tissue heterogeneity 
2. May relate to chemosensitivity 
and response to therapy 
3. Like traditional DWI, DKI is 
affected by cellularity. 
Sodium MRI  
(23Na- MRI) 
1. Non-invasively 
measures sodium 
concentration in 
tissue. 
2. Provides the second 
largest endogenous 
MR signal after the 
hydrogen nucleus.  
3. Requires a sodium 
coil and multi-
nuclear scanner 
4. Only feasible at 3T 
or higher due to 
low SNR 
5. Long scan times 
6. Sodium phantoms 
required for image 
calibration 
7. High SAR for IWS 
imaging. 
1. Inversely related to cellularity 
2. May detect fluid accumulation 
from oedema/inflammation 
3. Intracellular imaging may 
relate to tissue energy status 
and sodium transporter 
activity. 
Magnetization 
transfer (MT) 
imaging 
1. Fast scan and 
simple to acquire 
2. Widely studied and 
physical origin well 
understood  
1. Previously found to 
be of little clinical 
value in many 
diseases 
1. Cellularity measurement 
2. Tissue macromolecular 
content 
Hyperpolarized 
carbon-13 
spectroscopic 
imaging  
(HP 13C-MRI) 
1. Can provide real-
time information on 
metabolism. 
2. Can non-invasively 
map enzyme 
concentrations 
3. May detect early 
metabolic response 
to treatment 
4. Can measure 
downstream 
metabolites of 
pyruvate. 
1. Requires a 
hyperpolarizer in a 
separate nearby 
shielded room 
from scanner 
2. Requires 3T 
scanner or higher 
with multi-nuclear 
imaging 
capabilities. 
3. Long preparation 
time required to 
sufficiently polarize 
sample 
4. Expensive. 
1. LDH enzyme activity 
2. Endogenous lactate and 
pyruvate as these compete 
with C-13 labelled molecules 
and change the signal 
detected. 
3. MCT transporter 
concentration 
4. Tissue perfusion. 
18F-FDG-PET 1. Very sensitive at 
detecting increased 
metabolic activity 
2. Shown to be 
effective at imaging 
cancer and 
detecting 
metastases. 
3. Exposes patient 
and staff to 
radiation. 
4. Requires 
preparation of FDG 
prior to imaging. 
5. 60 to 90 minute 
waiting period 
required for uptake 
before imaging. 
1. Hexokinase enzyme activity 
2. GLUT transporter activity 
3. Tissue perfusion 
4. Cellularity 
5. Metabolism of glucose 
 
Magnetic resonance 
fingerprinting (MRF) 
1. Very fast 
2. Provides 
quantitative 
imaging 
1. Takes a long time 
to construct 
parameter maps 
due to the need to 
generate a library. 
2. New technique 
that is not well 
understood 
1. Can measure the T1, T2 and 
proton density of tissue in 
addition to other properties 
like diffusion if set-up to do so. 
 
Table 11.1: Summary of imaging techniques explored in this PhD 
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11.2 Future directions  
The DKI results presented here require verification with larger patient numbers. The clinical 
implications of predicting the response of HGSOC to cytotoxic treatment with a non-invasive 
imaging technique are great however the number of patients used in this study was very 
small and the results are consequently prone to error. 
The use of 23Na-MRI to measure tumour cellularity may complement conventional cellularity 
measurements with DWI, additionally by combining total sodium measurements with 
intracellular weighted sodium (IWS) imaging, it is possible to have a measure of cell 
membrane integrity. 23Na-MRI is affected by a variety of biological properties and 
comparison of imaging to tissue analysis is necessary to clarify the relative contributions of 
the different sodium transporters, perfusion effects, hypoxia and energy status changes in 
cancer. Higher field strength scanners such as 7T may improve the SNR of IWS imaging to 
detect the change in intracellular sodium with more specific physiological alterations in 
cancer.  
MT imaging is a well-established MRI technique but despite this, the biological significance 
of MT is still poorly understood. The significance of the tumour microenvironment is now 
becoming increasingly apparent in oncology and MT imaging could re-emerge in radiology 
as a probe of extracellular matrix if larger studies can confirm the relationships suggested by 
the preliminary results found here. 
HP 13C-MRI is a financially costly technique that requires unique imaging expertise to be 
present at the imaging site. It the technique is to be translated into clinical practice then the 
most influential biological determinants of the HP 13C-MRI signal must be determined to 
help identify a definite clinical application. There are a large number of possible biological 
properties of tissue that may affect the HP 13C-MRI signal and the relative contribution of 
each must be understood if the imaging technique is to be used clinically. One method of 
achieving this could be to compare HP 13C-MRI to tumour tissue derived at biopsy or 
surgery, where measurements have been made of the enzyme activities, transporter 
concentrations and endogenous metabolites concentrations. 
Another major direction of current work in HP 13C-MRI that was not explored in this PhD is 
the development of new tracers. The most promising options include carbon-13 labelled 
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fumarate whose metabolism to malate may be sensitive at detecting areas of necrosis 
within tumours (242). The challenges for fumarate imaging include the lower concentration 
of the tracer and the derived products compared to pyruvate and the relative lack of 
preclinical studies. The imaging of C-2 labelled pyruvate ([2-13C]pyruvate) is also being 
assessed as a potential human tracer since it facilitates the passage of the C-13 label deeper 
into the citric acid cycle where chemical reactions and enzyme activities other than PDC, 
ALT, LDH and CA can be studied. Recent unpublished data has shown that this type of 
imaging may have clinical utility in the brain and in the heart but its role in cancer is 
uncertain; possibly because relatively few tumours have sufficient PDH to assess 
metabolism. 
With the wide variety of MRI techniques available to clinicians and the unique information 
granted by each modality, the use more widespread use of MRF could allow multi-
parametric imaging to be performed with greater efficiency and in a more cost-effective 
manner. A comparison of MRF-generated images with images obtained through dedicated 
MRI sequences that builds on the preliminary results of this PhD could help to establish MRF 
as a viable replacement for some types of traditional MRI. 
The results of the research presented here emphasize the importance of expanding the use 
of clinical imaging from primarily a diagnostic tool used to obtain anatomical information 
into a role where it is used to address more relevant questions about tumour biology that 
can affect the way cancer is treated.  
In summary, there is significant scope for non-invasive imaging of metabolic and 
microstructural information in ovarian and other cancers and through the work of this PhD, 
it has been demonstrated that several novel imaging tools could report on the tumour 
microenviroment in HGSOC and could find roles in the clinic in the future. After the proof-
of-concept and feasibility study stages, the success of the imaging techniques studied here 
would eventually need to be evaluated against an outcome for patients such as progression 
free survival or an improvement in quality of life in prospective longitudinal trials as the 
ultimate goal of any medical imaging is to improve patient care.  
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